US20150273044A1 - Methods of inducing an immune response with compositions comprising a neisseria meningitidis 741 protein - Google Patents

Methods of inducing an immune response with compositions comprising a neisseria meningitidis 741 protein Download PDF

Info

Publication number
US20150273044A1
US20150273044A1 US14/739,985 US201514739985A US2015273044A1 US 20150273044 A1 US20150273044 A1 US 20150273044A1 US 201514739985 A US201514739985 A US 201514739985A US 2015273044 A1 US2015273044 A1 US 2015273044A1
Authority
US
United States
Prior art keywords
protein
seq
proteins
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/739,985
Inventor
Mariagrazia Pizza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Novartis AG
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9921633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20150273044(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to US14/739,985 priority Critical patent/US20150273044A1/en
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS S.R.L. reassignment NOVARTIS VACCINES AND DIAGNOSTICS S.R.L. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: CHIRON S.R.L.
Assigned to CHIRON S.R.L. reassignment CHIRON S.R.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PIZZA, MARIAGRAZIA
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS VACCINES AND DIAGNOSTICS SRL
Publication of US20150273044A1 publication Critical patent/US20150273044A1/en
Assigned to GLAXOSMITHKLINE BIOLOGICALS SA reassignment GLAXOSMITHKLINE BIOLOGICALS SA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS VACCINES AND DIAGNOSTICS SRL
Priority to US15/802,347 priority patent/US20180169210A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention is in the field of protein expression.
  • it relates to the expression of proteins from Neisseria (e.g. N. gonorrhoeae or, preferably, N. meningitidis ).
  • References 1 and 2 disclose alternative and improved approaches for the expression of the Neisserial proteins disclosed in references 3 to 6.
  • One such method is to produce ‘hybrid’ proteins in which two or more Neisserial proteins are expressed as a single polypeptide chain.
  • This approach offers two advantages. First, a protein that may be unstable or poorly expressed on its own can be assisted by adding a suitable hybrid partner that overcomes the problem. Second, commercial manufacture is simplified as only one expression and purification need be employed in order to produce two separately-useful proteins.
  • the invention provides a method for the simultaneous expression of two or more (e.g. 3, 4, 5, 6 or more) Neisserial proteins, in which said two or more proteins are joined such that they are translated as a single polypeptide chain.
  • the hybrid proteins of the invention can be represented by the formula: NH 2 -A-[—X-L-] n -B—COOH wherein X is an amino acid sequence, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than 1.
  • n is between 2 and x, and the value of x is typically 3, 4, 5, 6, 7, 8, 9 or 10.
  • each ⁇ X ⁇ moiety is:
  • a preferred subset of (a) is: orf46.1, 230, 287, 741, 919, 936, 953, 961 and 983.
  • a more preferred subset of (a) is: orf46.1, 287, 741 and 961.
  • FIG. 3 shows preferred hybrid proteins.
  • the hybrid protein comprises a first —X— moiety (—X a —) and a second —X— moiety (—X b —).
  • the —X a — moiety has one of the following amino acid sequences:
  • the —X b — moiety is related to —X a — such that: (i) —X b — has sequence identity to 13 X a —, and/or (j) —X b — comprises a fragment of —X a —.
  • this second type of hybrid protein examples include proteins in which two or more —X— moieties are identical, or in which they are variants of the same protein e.g. two polymorphic forms of the same protein may be expressed as —X a —X b —, and three polymorphic forms may be expressed as —X a —X b —X a — etc.
  • —X a — and —X b — moieties may be in either order from N-terminus to C-terminus.
  • the —X a — moiety is preferably an orf1, orf4, orf25, orf40, orf46.1, orf83, NMB1343, 230, 233, 287, 292, 594, 687, 736, 741, 907, 919, 936, 953, 961 or 983 amino acid sequence.
  • the —X a — moiety is more preferably an orf46.1, 230, 287, 741, 919, 936, 953, 961 or 983 amino acid sequence.
  • the —X a — moiety is most preferably an orf46.1, 287, 741 or 961 amino acid sequence.
  • the degree of ‘sequence identity’ referred to in (b) and (i) is preferably greater than 50% (eg. 60%, 70%, 80%, 90%, 95%, 99% or more, up to 100%). This includes mutants, homologs, orthologs, allelic variants etc. [e.g. see ref. 8].
  • fragment referred to in (c) and (j) should consist of least m consecutive amino acids from an amino acid sequence from (a), (d), (e), (f), (g) or (h) and, depending on the particular sequence, m is 7 or more (eg. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200 or more).
  • the fragment comprises an epitope from an amino acid sequence from (a), (d), (e), (t), (g) or (h).
  • Preferred fragments are those disclosed in references 9 and 10.
  • Preferred (c) and (j) fragments are C- and/or N-terminal truncations (e.g. ⁇ 1-287, A2-287 etc.).
  • Poly-glycine sequences can be represented as (Gly) g , where g>3 (e.g. 4, 5, 6, 7, 8, 9 or more). If a —X— moiety includes a poly-glycine sequence in its wild-type form, it is preferred to omit this sequence in the hybrid proteins of the invention. This may be by disrupting or removing the (Gly) g —by deletion (e.g. CGGGGS ⁇ CGGGS, CGGS, CGS or CS), by substitution (e.g.
  • Preferred (c) and (j) fragments omit complete protein domains. This is particularly useful for protein 961, 287, and ORF46. Once a protein has been notional divided into domains, (c) and (j) fragments can omit one or more of these domains (e.g. 287B, 287C, 287BC, ORF46 1-433 , ORF46 434-608 , 961c— reference 2; FIGS. 4 and 5 herein).
  • 287 protein has been notionally split into three domains, referred to as A, B & C (see FIG. 5 of reference 2).
  • Domain B aligns with IgA proteases
  • domain C aligns with transferrin-binding proteins
  • domain A shows no strong alignment with database sequences.
  • An alignment of polymorphic forms of 287 is disclosed in reference 8.
  • ORF46 has been notionally split into two domains—a first domain (amino acids 1-433; ORF46.1) which is well-conserved between species and serogroups, and a second domain (amino acids 434-608) which is not well-conserved.
  • the second domain is preferably deleted, leaving ORF46.1.
  • An alignment of polymorphic forms of ORF46 is disclosed in reference 8.
  • 961 protein has been notionally split into several domains ( FIG. 4 ).
  • a —X— moiety has a leader peptide sequence in its wild-type form, this may be included or omitted in the hybrid proteins of the invention. Where the leader peptide is omitted, this is a preferred example of an amino acid sequence within (c) and (j).
  • the leader peptides will be deleted except for that of the —X— moiety located at the N-terminus of the hybrid protein i.e. the leader peptide of X 1 will be retained, but the leader peptides of X 2 . . . X n will be omitted. This is equivalent to deleting all leader peptides and using the leader peptide of X 1 as moiety -A-.
  • preferred pairs of —X— moieties are: ⁇ G287 and 230; ⁇ G287 and 936; ⁇ G287 and 741; 961c and 287; 961c and 230; 961c and 936; 961cL and 287; 961cL and 230; 961cL and 936; ORF46.1 and 936; ORF46.1 and 230; 230 and 961; 230 and 741; 936 and 961; 936 and 741.
  • 287 is used in full-length form, it is preferably at the C-terminal end of a hybrid protein; if it is to be used at the N-terminus, if is preferred to use a ⁇ G form of 287.
  • 741 is used in full-length form, it is preferably at the C-terminal end of a hybrid protein; if it is to be used at the N-terminus, if is preferred to use a ⁇ G form of 741.
  • linker amino acid sequence -L- may be present or absent.
  • the hybrid may be NH 2 —X 1 -L 1 -X 2 -L 2 -COOH, NH 2 —X 1 —X 2 —COOH, NH 2 —X 1 -L 1 -X 2 —COOH, NH 2 —X 1 —X 2 -L 2 -COOH, etc.
  • a useful linker is GSGGGG (SEQ ID 27), with the Gly-Ser dipeptide being formed from a BamHI restriction site, thus aiding cloning and manipulation, and the Gly 4 tetrapeptide being a typical poly-glycine linker.
  • X n+1 is a ⁇ G protein and L n is a glycine linker, this may be equivalent to X n+1 not being a ⁇ G protein and L n being absent.
  • the invention can use amino acid sequences from any strains of N. meningitidis. References to a particular protein (e.g. ‘287’, or ‘ORF46.1’) therefore include that protein from any strain. Sequence variations between strains are included within (b), (c), (i) and (j).
  • Reference sequences from N. meningitidis serogroup B include:
  • Reference 8 discloses polymorphic forms of proteins ORF4, ORF40, ORF46, 225, 235, 287, 519, 726, 919 and 953. Polymorphic forms of 961 are disclosed in references 11 & 12. Any of these polymorphic forms may be used in accordance with the present invention.
  • sequence listing herein includes polymorphic forms of proteins 741 (SEQ IDs 1-22) and NMB 1343 (SEQ IDs 23-24) which have been identified.
  • Preferred proteins of the invention comprise —X— moieties having an amino acid sequence found in N. meningitidis serogroup B.
  • preferred —X— moieties are from strains 2996, MC58, 95N477, or 394/98.
  • Strain 95N477 is sometimes referred to herein as ‘ET37’, this being its electrophoretic type.
  • Strain 394/98 is sometimes referred to herein as ‘nz’, as it is a New Zealand strain.
  • this is preferably from strain 2996 or from strain 394/98.
  • this is preferably from serogroup B strains MC58, 2996, 394/98, or 95N477, or from serogroup C strain 90/18311.
  • this is preferably from strain 2996.
  • Strains are indicated as a subscript e.g. 741 MC58 is protein 741 from strain MC58. Unless otherwise stated, proteins mentioned herein (e.g. with no subscript) are from N. meningitidis strain 2996, which can be taken as a ‘reference’ strain. It will be appreciated, however, that the invention is not in general limited by strain. As mentioned above, general references to a protein (e.g. ‘287’, ‘919’ etc.) may be taken to include that protein from any strain. This will typically have sequence identity to 2996 of 90% or more (eg. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more).
  • References 1 and 2 disclose how a protein can be notionally divided into domains and how the protein can be manipulated based on these domains.
  • the present invention extends the application of this approach to protein 961 (also known as ‘NadA’ [11,12]).
  • NadA has 405 amino acids. This protein has notionally been divided into the following nine domains ( FIG. 4 ):
  • This information can be used to locate the same domains in other forms of 961.
  • fragments are preferred (c) and (j) fragments, but they may also be expressed in their own right i.e. not in the form of a hybrid protein of the invention.
  • the invention provides a protein comprising one of these fragments, providing that the protein is not full-length 961 and is not a protein specifically disclosed in reference 1 or 2.
  • This protein may be a fusion protein (e.g. a GST-fusion or a His-tag fusion).
  • the invention also provides a protein having an amino acid sequence from SEQ IDs 1 to 24. It also provides proteins and nucleic acid having sequence identity to these. As described above, the degree of ‘sequence identity’ is preferably greater than 50% (eg. 60%, 70%, 80%, 90%, 95%, 99% or more).
  • the invention also provides nucleic acid encoding such proteins.
  • nucleic acid which can hybridise to this nucleic acid, preferably under “high stringency” conditions (eg. 65° C. in a 0.1 ⁇ SSC, 0.5% SDS solution).
  • the invention also provides nucleic acid encoding proteins according to the invention.
  • nucleic acid comprising sequences complementary to those described above (eg. for antisense or probing purposes).
  • Nucleic acid according to the invention can, of course, be prepared in many ways (eg. by chemical synthesis, from genomic or cDNA libraries, from the organism itself etc.) and can take various forms (eg. single stranded, double stranded, vectors, probes etc.).
  • nucleic acid includes DNA and RNA, and also their analogues, such as those containing modified backbones, and also peptide nucleic acids (PNA) etc.
  • PNA peptide nucleic acids
  • the invention also provides a composition comprising two or more (i.e. 2, 3, 4, 5, 6 or 7) of the following proteins:
  • the mixture may include one or both of the following proteins, either in combination with two or more of (1) to (7), or in combination with only one of (1) to (7):
  • proteins 287 and 741 are included in the mixture (i.e. in protein 1, 2, 5, 6, 7 or 8), they may be in the ‘ ⁇ G’ form. Where protein 961 is included, it is preferably in the form of ‘961c’ in which the N-terminus leader and C-terminus membrane anchor are absent [e.g. see refs. 1, 2 & 11].
  • a preferred mixture comprises the following three proteins:
  • the mixtures may also comprise N. meningitidis outer membrane vesicles.
  • heterologous host Whilst expression of the proteins of the invention may take place in Neisseria, the present invention preferably utilises a heterologous host.
  • the heterologous host may be prokaryotic (e.g. a bacterium) or eukaryotic. It is preferably E. coli, but other suitable hosts include Bacillus subtilis, Vibrio cholerae, Salmonella typhi, Salmonenna typhimurium, Neisseria lactamica, Neisseria cinerea, Mycobacteria (e.g. M. tuberculosis ), yeast etc.
  • the invention provides (a) nucleic acid encoding the proteins described above (b) vectors comprising these nucleic acid sequences (c) host cells containing said vectors (d) compositions comprising the proteins or nucleic acids of the invention, which may be suitable as immunogenic compositions (e.g. vaccines) or as diagnostic reagents (e) these compositions for use as medicaments (e.g.
  • compositions for treating or preventing infection due to Neisserial bacteria
  • diagnostic reagent for detecting the presence of Neisserial bacteria or of antibodies raised against Neisseria bacteria
  • a reagent which can raise antibodies against Neisseria bacteria for detecting the presence of Neisserial bacteria or of antibodies raised against Neisseria bacteria
  • a method of treating a patient comprising administering to the patient a therapeutically effective amount of these compositions.
  • Implementing the invention will typically involve the basic steps of: obtaining a first nucleic acid encoding a first protein; obtaining a second nucleic acid encoding a second protein; and ligating the first and second nucleic acids.
  • the resulting nucleic acid may be inserted into an expression vector, or may already be part of an expression vector.
  • purification of hybrid proteins may involve the refolding techniques disclosed herein.
  • compositions of the invention are preferably immunogenic composition, and are more preferably vaccine compositions.
  • the pH of the composition is preferably between 6 and 7.
  • the pH may be maintained by the use of a buffer.
  • the composition may be sterile.
  • Vaccines according to the invention may either be prophylactic (i.e. to prevent infection) or therapeutic (i.e. to treat infection), but will typically be prophylactic.
  • the invention also provides a composition of the invention for use as a medicament.
  • the medicament is preferably able to raise an immune response in a mammal (i.e. it is an immunogenic composition) and is more preferably a vaccine.
  • the invention also provides the use of a composition of the invention in the manufacture of a medicament for raising an immune response in a mammal.
  • the medicament is preferably a vaccine.
  • the invention also provides a method for raising an immune response in a mammal comprising the step of administering an effective amount of a composition of the invention.
  • the immune response is preferably protective.
  • the method may raise a booster response.
  • the mammal is preferably a human.
  • the human is preferably a child (e.g. a toddler or infant); where the vaccine is for prophylactic use, the human is preferably an adult.
  • a vaccine intended for children may also be administered to adults e.g. to assess safety, dosage, immunogenicity, etc.
  • These uses and methods are preferably for the prevention and/or treatment of a disease caused by a Neisseria (e.g. meningitis, septicaemia, gonorrhoea etc.).
  • a Neisseria e.g. meningitis, septicaemia, gonorrhoea etc.
  • the prevention and/or treatment of bacterial meningitis is preferred.
  • composition of the invention will typically, in addition to the components mentioned above, comprise one or more ‘pharmaceutically acceptable carriers’, which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition.
  • Suitable carriers are typically large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, trehalose (WO00/56365) and lipid aggregates (such as oil droplets or liposomes).
  • lipid aggregates such as oil droplets or liposomes.
  • the vaccines may also contain diluents, such as water, saline, glycerol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering substances, and the like, may be present.
  • Immunogenic compositions used as vaccines comprise an immunologically effective amount of antigen, as well as any other of the above-mentioned components, as needed.
  • immunologically effective amount it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (e.g. non-human primate, primate, etc.), the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors.
  • Dosage treatment may be a single dose schedule or a multiple dose schedule (e.g. including booster doses).
  • the vaccine may be administered in conjunction with other immunoregulatory agents.
  • the vaccine may be administered in conjunction with other immunoregulatory agents.
  • the composition may include other adjuvants in addition to (or in place of) the aluminium salt.
  • Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59TM (WO90/14837; Chapter 10 in ref.
  • RibiTM adjuvant system Ribi Immunochem, Hamilton, Mont.
  • MPL monophosphorylipid A
  • TDM trehalose dimycolate
  • CWS cell wall skeleton
  • saponin adjuvants such as QS21 or StimulonTM
  • cytokines such as interleukins (e.g. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 (WO99/44636), etc.), interferons (e.g. gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; (5) monophosphoryl lipid A (MPL) or 3-0-deacylated MPL (3dMPL) e.g.
  • MPL monophosphoryl lipid A
  • 3dMPL 3-0-deacylated MPL
  • a polyoxyethylene sorbitan ester surfactant in combination with an octoxynol e.g. WO01/21207 or a polyoxyethylene alkyl ether or ester surfactant in combination with at least one additional non-ionic surfactant such as an octoxynol (e.g. WO01/21152);
  • an immunostimulatory oligonucleotide e.g. a CpG oligonucleotide
  • a saponin e.g. WO00/62800
  • an immunostimulant and a particle of metal salt e.g.
  • WO00/23105 (12) a saponin and an oil-in-water emulsion e.g. WO99/11241; (13) a saponin (e.g. QS21)+3dMPL+IL-12 (optionally+a sterol) e.g. WO98/57659; (14) other substances that act as immunostimulating agents to enhance the efficacy of the composition.
  • Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE), etc.
  • thr-MDP N-acetyl-muramyl-L-threonyl-D-isoglutamine
  • nor-MDP N-acetyl-normuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxy
  • composition of the invention include:
  • composition may comprise one or more of these further antigens.
  • a saccharide or carbohydrate antigen is used, it is preferably conjugated to a carrier protein in order to enhance immunogenicity [e.g. refs. 54 to 63].
  • Preferred carrier proteins are bacterial toxins or toxoids, such as diphtheria or tetanus toxoids.
  • the CRM 197 diphtheria toxoid is particularly preferred.
  • Other suitable carrier proteins include the N. meningitidis outer membrane protein [e.g. ref. 64], synthetic peptides [e.g. 65, 66], heat shock proteins [e.g. 67], pertussis proteins [e.g. 68, 69], protein D from H. influenzae [e.g. 70], toxin A or B from C. difficile [e.g.
  • a mixture comprises capsular saccharides from both serogroups A and C
  • the ratio (w/w) of MenA saccharide:MenC saccharide is greater than 1 (e.g. 2:1, 3:1, 4:1, 5:1, 10:1 or higher).
  • Saccharides from different serogroups of N. meningitidis may be conjugated to the same or different carrier proteins.
  • Toxic protein antigens may be detoxified where necessary (e.g. detoxification of pertussis toxin by chemical and/or genetic means [32]).
  • diphtheria antigen is included in the composition it is preferred also to include tetanus antigen and pertussis antigens. Similarly, where a tetanus antigen is included it is preferred also to include diphtheria and pertussis antigens. Similarly, where a pertussis antigen is included it is preferred also to include diphtheria and tetanus antigens.
  • Antigens are preferably mixed with (and more preferably adsorbed to) an aluminium salt (e.g. phosphate, hydroxide, hydroxyphosphate, oxyhydroxide, orthophosphate, sulphate).
  • the salt may take any suitable form (e.g. gel, crystalline, amorphous etc.).
  • Antigens in the composition will typically be present at a concentration of at least 1 ⁇ g/ml each. In general, the concentration of any given antigen will be sufficient to elicit an immune response against that antigen.
  • nucleic acid encoding the antigen may be used [e.g. refs. 72 to 80]. Protein components of the compositions of the invention may thus be replaced by nucleic acid (preferably DNA e.g. in the form of a plasmid) that encodes the protein.
  • composition “comprising” means “including” as well as “consisting” e.g. a composition “comprising” X may consist exclusively of X or may include something additional e.g. X+Y.
  • FIG. 1 shows an alignment of twenty-three sequences for protein 741. These are SEQ IDs 1 to 22 plus the sequence from MC58.
  • FIG. 2 shows an alignment of the NMB 1343 sequence from gonococcus (top; SEQ ID 25) and meningococcus (bottom; SEQ ID 26).
  • FIG. 3 shows hybrid and tandem proteins of the invention.
  • FIG. 4 shows 9 domains within 961 2996
  • FIG. 5 shows how these have been manipulated.
  • FCA Freund's complete adjuvant
  • mice were immunised with of three proteins adjuvanted with aluminium hydroxide, either single or in a triple combination: (1) 287 NZ -953; (2) 936-741; and (3) 961c. The mixture was able to induce high bactericidal titres against various strains:
  • Hybrid proteins of the invention can be represented by formula NH 2 —[—X-L-] n -COOH. Where all n instances of —X— are the same basic protein (either identical, or the same protein from different strains or species), the protein is referred to as a ‘tandem’ protein.
  • Proteins #1 to #5 have all been expressed in soluble form in E. coli. Expression levels were between 0.24 and 0.50 mg protein per litre of culture. The tandem proteins were purified and mixed with aluminium phosphate as an adjuvant. Tandem proteins #2, #4 and #5 adsorbed readily to aluminium phosphate; adsorption was less complete for tandem proteins #1 and #3.
  • NMB1343 protein was found in 24/42 and was absent in 18/42 strains (Table 1).
  • the NMB gene was sequenced for 10 of the NMB1343 + strains (Table 1, column 3).
  • the nucleic acid sequence (and thus amino acid sequence SEQ ID 23; GenBank AAF41718) was identical in all 10 strains.
  • NMB1343 was also detected in two strains of N. gonorrhoeae (F62 and SN4).
  • the amino acid sequence from gonococcus is SEQ ID 24.
  • An alignment with the meningococcal sequence is:
  • FIG. 2 An alignment of the corresponding nucleotide sequences is shown in FIG. 2 . This shows that the gonococcal sequence has a 4 mer insertion in the 5′ region of the NMB1343 gene which causes a frameshift and consequent loss of the 5′ methionine residue.
  • 961 is not present in the N. meningitidis serogroup A genome sequence [81], even though the surrounding regions are conserved (>90%) between serogroups A and B.
  • References 11 and 12 disclose polymorphic forms of 961. The gene was found to be present in 91% of serogroup B strains belonging to hypervirulent lineages ET-5, ET-37 and cluster A4, but was absent in all strains of lineage 3 tested. Most of the serogroup C strains tested were positive even if not belonging to hypervirulent lineages. The same was true for the serogroup B strains with serotype 2a and 2b. For serogroup A, one strain belonging to subgroup III was positive whereas the other two strains belonging to subgroup IV-1 were negative. 961 was absent in N. gonorrhoeae and in commensal species N. lactamica and N. cinerea.
  • FIGS. 4 and 5 show domains in protein 961.
  • deletion mutants in the C-terminal region of 961 were constructed (961cL- ⁇ aro, 961cL ⁇ cc, 961aL, 961aL- ⁇ 1, 961aL- ⁇ 2, 961aL- ⁇ 3) on the basis of structural features (deletions of aromatic residues in the cases of 961c ⁇ aro mutant, and of coiled-coil regions for the others). These were analysed for expression and secretion into the periplasm and the supernatant of the culture. In all of these deletion mutants, the protein is produced in large amount, is present in periplasmic fraction, and is released in the supernatant of the culture.
  • Protein Sera tested for bactericidal activity against strain* strain 2996 BZ232 MC58 1000 394/98 F6124 BZ133 2996 16000 128 4096 4096 1024 8000 16000 BZ232 >8000 256 2048 8000 2048 16000 8000 MC58 >8000 64 >8000 8000 2048 8000 8000 1000 >8000 64 4096 8000 1024 16000 16000 394/98 >16000 128 16000 >2048 >16000 — — * samples against homologous strain shown in bold
  • Hybrid proteins were expressed in E. coli as follows:
  • pellets were solubilised, refolded, ultrafiltered, dialysed, and protein was then purified:
  • IB proteins were solubilised as follows: IB proteins were resuspended in 4 ml of 6M guanidine HCl, 1 mM EDTA pH 8.5 buffer, to a final protein concentration of 1 mg/ml. To refold the protein, 2 ml of solubilised protein was diluted in 400 ml of refolding buffer (0.1M Tris HCl, 1M L-arginine, 2 mM EDTA pH 8.2) and incubated for 1 hour at 15° C., resulting in a protein concentration of 5 ⁇ g/ml.
  • refolding buffer 0.1M Tris HCl, 1M L-arginine, 2 mM EDTA pH 8.2
  • a second dialysis of 24 h against 10 L of 300 mM NaCl, 50 mM sodium phosphate pH 8.0 buffer was performed.
  • the dialysed material was centrifuged at 22000 rpm for 45 minutes at 4° C. in a Beckman centrifuge rotor JA25.5 The supernatant isolated after centrifugation was used for His-tag purification.
  • IB proteins were solubilised as follows: IB proteins were resuspended in 4 ml of 6M guanidine HCl, 1 mM EDTA pH 8.5 buffer, to a final protein concentration of 1 mg/ml. To refold the protein, 2 ml of the solubilised protein was diluted in 400 ml refolding buffer (0.5M Tris HCl, 1M L-arginine, 2 mM EDTA pH 8.2) and incubated for 1 h at 15° C., resulting in a protein concentration of 5 ⁇ g/ml.
  • refolding buffer 0.5M Tris HCl, 1M L-arginine, 2 mM EDTA pH 8.2
  • a second dialysis of 24 h against 10 L of 300 mM NaCl, 50 mM sodium phosphate pH 8.0 buffer was performed.
  • the dialysed material was centrifuged at 22000 rpm for 45 minutes at 4° C. in a Beckman centrifuge rotor JA25.5.
  • the supernatant isolated after centrifugation was used for His-tag purification.
  • IBs 961c-orf46.1-His IBs were solubilised as follows: IB proteins were resuspended in 4 ml of 6M guanidine HCl, 1 mM EDTA pH 8.5 buffer, to a final protein concentration of 1 mg/ml. To refold the protein, 2 ml of the solubilised protein was diluted in 400 ml refolding buffer (0.1M Tris HCl, 0.5 M L-arginine,2 mM EDTA pH 8.2) and incubated for 1 h at 15° C., resulting in a protein concentration of 5 ⁇ g/ml.
  • refolding buffer 0.1M Tris HCl, 0.5 M L-arginine,2 mM EDTA pH 8.2
  • a second dialysis of 24 h against 10 L of 300 mM NaCl, 50 mM sodium phosphate pH 8.0 buffer was performed.
  • the dialysed material was centrifuged at 22000 rpm for 45 minutes at 4° C. in a Beckman centrifuge rotor JA25.5.
  • the supernatant isolated after centrifugation was used for His-tag purification.
  • IB proteins were solubilised as follows: IB proteins were resuspended in 4 ml of 6M guanidine HCl, 1 mM EDTA pH 8.5 buffer, to a final protein concentration of 10 mg/ml. To refold, 2 ml of the solubilised protein was diluted in 400 ml of the refolding buffer (0.5M Tris HCl, 0.7 M L-arginine, 2 mM EDTA pH 7.2) and incubated for 1 h at 15° C., resulting in a protein concentration of 50 ⁇ g/ml.
  • the refolding buffer 0.5M Tris HCl, 0.7 M L-arginine, 2 mM EDTA pH 7.2
  • a second dialysis of 24 h against 10 L of 300 mM NaCl, 50 mM sodium phosphate pH 8.0 buffer was performed.
  • the dialysed material was centrifuged at 22000 rpm for 45 minutes at 4° C. in a Beckman centrifuge rotor JA25.5 The supernatant isolated after centrifugation was used for His-tag purification.
  • bactericidal assay titres were as follows:
  • ORF46.1K Similar procedures were used for ORF46.1 to purify the protein from IBs when expressed with no His-tag (‘ORF46.1K’):
  • IB proteins were resuspended in 4 ml of 6M guanidine HCl, 1 mM EDTA pH 8.5 buffer, to a final protein concentration of 10 mg/ml.
  • 2 ml of the solubilised protein was diluted in 400 ml of the refolding buffer (0.5M Tris HCl, 0.7 M L-arginine,2 mM EDTA pH 7.2) and incubated for 1 hours at 15° C., resulting in a protein concentration of 50 ⁇ g/ml. Subsequently another 2 ml of the solubilised protein was added and incubated for an additional hour at the same temperature resulting in a final protein concentration of 100 m/ml.
  • the refolding buffer 0.5M Tris HCl, 0.7 M L-arginine,2 mM EDTA pH 7.2
  • the material was ultrafiltered using a 300 ml Amicon ultrafiltration cell (8400), applying a 3 bar pressure on an Amicon membrane with a 30 kDa cut-off (YM30) resulting in 120 ml final volume.
  • the ultrafiltered material was dialysed using a regenerated cellulose tubular membrane with a 12-14 kDa cutoff (Cellusep—Step bio) for 12 h against 10 L of 50 mM sodium phosphate, 2 mM EDTA, pH 7.2 buffer. A second dialysis of 24 h against 10 L of the same buffer was performed.
  • the dialysed material was centrifuged at 22000 rpm for 45 minutes at 4° C. in a Beckman centrifuge rotor JA25.5.
  • the supernatant isolated after centrifugation was used for cationic exchange chromatography.
  • the purification was done on a AKTA explorer chromatography system (Amersham-Pharmacia Biotech) using a 5 ml HiTrap SP sepharose HP column (Amersham-Pharmacia Biotech). The flow rate applied was of 1.5 ml per minute.
  • the column was washed with 35 ml of 50 mM sodium phosphate buffer pH 7.2.
  • a linear gradient (0-1 M NaCl) was performed using a 50 mM sodium phosphate buffer pH 7.2.
  • the protein eluted in two peaks at 92 mM and 380 mM NaCl.
  • the fractions constituting each peak were pooled and respectively named pool 1 and pool 2.
  • bactericidal assay titres when adjuvanted with aluminium hydroxide were improved from ⁇ 4 to 1024.
  • the titre using aluminium phosphate adjuvant with the refolded protein was 2048.
  • ELISA titres were as follows:

Abstract

Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH2-A-[—X-L-]n-B—COOH where X is an amino acid sequence, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than 1. Proteins where each of the n-X— moieties shares sequence identity to each other —X— moiety, the protein is a ‘tandem protein’.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a Continuation of U.S. patent application Ser. No. 14/305,979, filed Jun. 16, 2014, now U.S. Pat. No. 9,056,075; which is a Divisional of U.S. patent application Ser. No. 13/366,252, filed Feb. 3, 2012, now U.S. Pat. No. 8,840,907; which is a Divisional of U.S. patent application Ser. No. 10/488,786, which claims an international filing date of Sep. 6, 2002, now U.S. Pat. No. 8,980,277; which is the National Stage of International Patent Application No. PCT/IB2002/003904, filed Sep. 6, 2002; which claims the benefit of United Kingdom Patent Application No. 0121591.2, filed Sep. 6, 2001; the disclosures of which are herein incorporated by reference in their entirety.
  • All documents cited herein are incorporated by reference in their entirety.
    • SUBMISSION OF SEQUENCE LISTING AS ASCII TEXT FILE
  • The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 223002100602SeqList.txt, date recorded: Jun. 12, 2015, size: 70 KB).
    • TECHNICAL FIELD
  • This invention is in the field of protein expression. In particular, it relates to the expression of proteins from Neisseria (e.g. N. gonorrhoeae or, preferably, N. meningitidis).
    • BACKGROUND ART
  • References 1 and 2 disclose alternative and improved approaches for the expression of the Neisserial proteins disclosed in references 3 to 6. One such method is to produce ‘hybrid’ proteins in which two or more Neisserial proteins are expressed as a single polypeptide chain. This approach offers two advantages. First, a protein that may be unstable or poorly expressed on its own can be assisted by adding a suitable hybrid partner that overcomes the problem. Second, commercial manufacture is simplified as only one expression and purification need be employed in order to produce two separately-useful proteins.
  • It is an object of the present invention to provide further alternative and improved approaches for the expression of Neisserial proteins.
    • DISCLOSURE OF THE INVENTION
  • Hybrid Proteins
  • Thus the invention provides a method for the simultaneous expression of two or more (e.g. 3, 4, 5, 6 or more) Neisserial proteins, in which said two or more proteins are joined such that they are translated as a single polypeptide chain. In general, the hybrid proteins of the invention can be represented by the formula: NH2-A-[—X-L-]n-B—COOH wherein X is an amino acid sequence, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than 1.
  • The value of n is between 2 and x, and the value of x is typically 3, 4, 5, 6, 7, 8, 9 or 10. Preferably n is 2, 3 or 4; it is more preferably 2 or 3; most preferably, n=2.
  • The ˜X˜ Moieties
  • There are two main groups of hybrid proteins according to the invention. These two groups are not mutually exclusive.
  • In the first group, each ˜X˜ moiety is:
      • (a) an orf1, orf4, orf25, orf40, orf46.1, orf83, NMB1343, 230, 233, 287, 292, 594, 687, 736, 741, 907, 919, 936, 953, 961 or 983 amino acid sequence;
      • (b) an amino acid sequence having sequence identity to an amino acid sequence from (a); or
      • (c) an amino acid sequence comprising a fragment of an amino acid sequence from (a).
  • A preferred subset of (a) is: orf46.1, 230, 287, 741, 919, 936, 953, 961 and 983. A more preferred subset of (a) is: orf46.1, 287, 741 and 961. FIG. 3 shows preferred hybrid proteins.
  • In the second group, the hybrid protein comprises a first —X— moiety (—Xa—) and a second —X— moiety (—Xb—). The —Xa— moiety has one of the following amino acid sequences:
      • (d) the 446 even SEQ IDs (i.e. 2, 4, 6, . . . , 890, 892) disclosed in reference 3.
      • (e) the 45 even SEQ IDs (i.e. 2, 4, 6, . . . , 88, 90) disclosed in reference 4;
      • (f) the 1674 even SEQ IDs 2-3020, even SEQ IDs 3040-3114, and all SEQ IDs 3115-3241, disclosed in reference 5;
      • (g) the 2160 amino acid sequences NMB0001 to NMB2160 from reference 7; or
      • (h) an amino acid sequence disclosed in reference 1 or reference 2.
  • The —Xb— moiety is related to —Xa— such that: (i) —Xb— has sequence identity to 13 Xa—, and/or (j) —Xb— comprises a fragment of —Xa—.
  • Examples of this second type of hybrid protein include proteins in which two or more —X— moieties are identical, or in which they are variants of the same protein e.g. two polymorphic forms of the same protein may be expressed as —Xa—Xb—, and three polymorphic forms may be expressed as —Xa—Xb—Xa— etc.
  • The —Xa— and —Xb— moieties may be in either order from N-terminus to C-terminus.
  • The —Xa— moiety is preferably an orf1, orf4, orf25, orf40, orf46.1, orf83, NMB1343, 230, 233, 287, 292, 594, 687, 736, 741, 907, 919, 936, 953, 961 or 983 amino acid sequence. The —Xa— moiety is more preferably an orf46.1, 230, 287, 741, 919, 936, 953, 961 or 983 amino acid sequence. The —Xa— moiety is most preferably an orf46.1, 287, 741 or 961 amino acid sequence.
  • In proteins where each of the n-X— moieties shares sequence identity to each other —X— moiety, the protein is referred to as a ‘tandem protein’. Tandem proteins in which n=2 are preferred.
  • The degree of ‘sequence identity’ referred to in (b) and (i) is preferably greater than 50% (eg. 60%, 70%, 80%, 90%, 95%, 99% or more, up to 100%). This includes mutants, homologs, orthologs, allelic variants etc. [e.g. see ref. 8]. Identity is preferably determined by the Smith-Waterman homology search algorithm as implemented in the MPSRCH program (Oxford Molecular), using an affine gap search with parameters gap open penalty=12 and gap extension penalty=1. Typically, 50% identity or more between two proteins is considered as an indication of functional equivalence.
  • The ‘fragment’ referred to in (c) and (j) should consist of least m consecutive amino acids from an amino acid sequence from (a), (d), (e), (f), (g) or (h) and, depending on the particular sequence, m is 7 or more (eg. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200 or more).
  • Preferably the fragment comprises an epitope from an amino acid sequence from (a), (d), (e), (t), (g) or (h). Preferred fragments are those disclosed in references 9 and 10.
  • Preferred (c) and (j) fragments are C- and/or N-terminal truncations (e.g. Δ1-287, A2-287 etc.).
  • Preferred (b), (c), (i) and (j) sequences omit poly-glycine sequences. This has been found to aid expression [ref. 2]. Poly-glycine sequences can be represented as (Gly)g, where g>3 (e.g. 4, 5, 6, 7, 8, 9 or more). If a —X— moiety includes a poly-glycine sequence in its wild-type form, it is preferred to omit this sequence in the hybrid proteins of the invention. This may be by disrupting or removing the (Gly)g—by deletion (e.g. CGGGGS→CGGGS, CGGS, CGS or CS), by substitution (e.g. CGGGGS→CGXGGS, CGXXGS, CGXGXS etc.), and/or by insertion (e.g. CGGGGS→CGGXGGS, CGXGGGS, etc.). Deletion of (Gly)g is preferred, and deletion of the N-terminus portion of a protein up to and including the poly-glycine sequence (e.g. deletion of residues 1-32 in SEQ ID 1) is referred to herein as ‘ΔG’. Poly-glycine omission is particularly useful for proteins 287, 741, 983 and Tbp2 (ΔG287, ΔG741, ΔG983 and ΔGTbp2—references 1 & 2).
  • Preferred (c) and (j) fragments omit complete protein domains. This is particularly useful for protein 961, 287, and ORF46. Once a protein has been notional divided into domains, (c) and (j) fragments can omit one or more of these domains (e.g. 287B, 287C, 287BC, ORF461-433, ORF46434-608, 961c— reference 2; FIGS. 4 and 5 herein).
  • 287 protein has been notionally split into three domains, referred to as A, B & C (see FIG. 5 of reference 2). Domain B aligns with IgA proteases, domain C aligns with transferrin-binding proteins, and domain A shows no strong alignment with database sequences. An alignment of polymorphic forms of 287 is disclosed in reference 8.
  • ORF46 has been notionally split into two domains—a first domain (amino acids 1-433; ORF46.1) which is well-conserved between species and serogroups, and a second domain (amino acids 434-608) which is not well-conserved. The second domain is preferably deleted, leaving ORF46.1. An alignment of polymorphic forms of ORF46 is disclosed in reference 8.
  • 961 protein has been notionally split into several domains (FIG. 4).
  • If a —X— moiety has a leader peptide sequence in its wild-type form, this may be included or omitted in the hybrid proteins of the invention. Where the leader peptide is omitted, this is a preferred example of an amino acid sequence within (c) and (j). In one embodiment, the leader peptides will be deleted except for that of the —X— moiety located at the N-terminus of the hybrid protein i.e. the leader peptide of X1 will be retained, but the leader peptides of X2 . . . Xn will be omitted. This is equivalent to deleting all leader peptides and using the leader peptide of X1 as moiety -A-.
  • When n=2, preferred pairs of —X— moieties are: ΔG287 and 230; ΔG287 and 936; ΔG287 and 741; 961c and 287; 961c and 230; 961c and 936; 961cL and 287; 961cL and 230; 961cL and 936; ORF46.1 and 936; ORF46.1 and 230; 230 and 961; 230 and 741; 936 and 961; 936 and 741. When n=2, preferred pairs of —X— moieties for tandem proteins are: ΔG741 and 741; ΔG287 and 287. More specifically, the following combinations of X1 and X2 are preferred when n=2:
  • X1 X2
    ΔG287 230
    ΔG287 936
    ΔG287 741
    ΔG287 961
    ΔG287 ORF46.1
    ΔG287 919
    ΔG287 953
    961c 287
    961c 230
    961c 936
    961c 741
    961c 983
    961c ΔG983
    961c ORF46.1
    961 ORF46.1
    961cL 287
    961cL 230
    961cL 936
    ORF46.1 936
    ORF46.1 230
    ORF46.1 741
    ORF46.1 ΔG741
    ORF46.1 983
    ORF46.1 ΔG983
    230 961
    230 741
    230 ΔG741
    936 961
    936 741
    936 ΔG741
    ΔG741
    741
    ORF46.1 983
    ΔG741 ORF46.1
    ΔG741 983
    ΔG741 961
    ΔG741 961c
    ΔG983 ORF46.1
    ΔG983 961
    ΔG983 961c
    230 ΔG287
    936 ΔG287
    741 ΔG287
    961 ΔG287
    ORF46.1 ΔG287
    919 ΔG287
    953 ΔG287
    287 961c
    230 961c
    936 961c
    741 961c
    983 961c
    ΔG983
    961c
    ORF46.1 961c
    ORF46.1 961
    287 961cL
    230 961cL
    936 961cL
    936 ORF46.1
    230 ORF46.1
    741 ORF46.1
    ΔG741 ORF46.1
    983 ORF46.1
    ΔG983 ORF46.1
    961 230
    741 230
    ΔG741 230
    961 936
    741 936
    ΔG741 936
    ΔG287 287
    983 ORF46.1
    ORF46.1 ΔG741
    983 ΔG741
    961 ΔG741
    961c ΔG741
    ORF46.1 ΔG983
    961 ΔG983
    961c ΔG983
  • Where 287 is used in full-length form, it is preferably at the C-terminal end of a hybrid protein; if it is to be used at the N-terminus, if is preferred to use a ΔG form of 287. Similarly, Where 741 is used in full-length form, it is preferably at the C-terminal end of a hybrid protein; if it is to be used at the N-terminus, if is preferred to use a ΔG form of 741.
  • The -L- Moieties
  • For each n instances of [—X-L-], linker amino acid sequence -L- may be present or absent. For instance, when n=2 the hybrid may be NH2—X1-L1-X2-L2-COOH, NH2—X1—X2—COOH, NH2—X1-L1-X2—COOH, NH2—X1—X2-L2-COOH, etc.
  • Linker amino acid sequence(s) -L- will typically be short (e.g. 20 or fewer amino acids i.e. 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples include short peptide sequences which facilitate cloning, poly-glycine linkers (i.e. Glyn where n=2, 3, 4, 5, 6, 7, 8, 9, 10 or more), and histidine tags (i.e. Hisn where n=3, 4, 5, 6, 7, 8, 9, 10 or more). Other suitable linker amino acid sequences will be apparent to those skilled in the art. A useful linker is GSGGGG (SEQ ID 27), with the Gly-Ser dipeptide being formed from a BamHI restriction site, thus aiding cloning and manipulation, and the Gly4 tetrapeptide being a typical poly-glycine linker.
  • If Xn+1 is a ΔG protein and Ln is a glycine linker, this may be equivalent to Xn+1 not being a ΔG protein and Ln being absent.
  • The -A- Moiety
  • -A- is an optional N-terminal amino acid sequence. This will typically be short (e.g. 40 or fewer amino acids i.e. 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples include leader sequences to direct protein trafficking, or short peptide sequences which facilitate cloning or purification (e.g. histidine tags i.e. Hisn where n=3, 4, 5, 6, 7, 8, 9, 10 or more). Other suitable N-terminal amino acid sequences will be apparent to those skilled in the art. If X1 lacks its own N-terminus methionine, -A- may be a methionine residue.
  • The —B— Moiety
  • —B— is an optional C-terminal amino acid sequence. This will typically be short (e.g. 40 or fewer amino acids i.e. 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples include sequences to direct protein trafficking, short peptide sequences which facilitate cloning or purification (e.g. comprising histidine tags i.e. Hisn where n=3, 4, 5, 6, 7, 8, 9, 10 or more), or sequences which enhance protein stability. Other suitable C-terminal amino acid sequences will be apparent to those skilled in the art.
  • Polymorphic Forms of Proteins
  • The invention can use amino acid sequences from any strains of N. meningitidis. References to a particular protein (e.g. ‘287’, or ‘ORF46.1’) therefore include that protein from any strain. Sequence variations between strains are included within (b), (c), (i) and (j).
  • Reference sequences from N. meningitidis serogroup B include:
  • Protein Reference
    orf1 Ref. 3, SEQ ID 650
    orf25 Ref. 3, SEQ ID 684
    orf46 Ref. 6, SEQ ID 1049
    NMB1343 Ref. 7, NMB1343
    233 Ref. 5, SEQ ID 860
    292 Ref. 5, SEQ ID 1220
    687 Ref. 5, SEQ ID 2282
    741 Ref. 5, SEQ ID 2536
    919 Ref. 5, SEQ ID 3070
    953 Ref. 5, SEQ ID 2918
    983 Ref. 7, NMB1969
    orf4 Ref. 3, SEQ ID 218
    orf40 Ref. 4, SEQ ID 4
    orf83 Ref. 3, SEQ ID 314
    230 Ref. 5, SEQ ID 830
    287 Ref. 5, SEQ ID 3104
    594 Ref. 5, SEQ ID 1862
    736 Ref. 5, SEQ ID 2506
    907 Ref. 5, SEQ ID 2732
    936 Ref. 5, SEQ ID 2884
    961 Ref. 5, SEQ ID 940
  • Reference 8 discloses polymorphic forms of proteins ORF4, ORF40, ORF46, 225, 235, 287, 519, 726, 919 and 953. Polymorphic forms of 961 are disclosed in references 11 & 12. Any of these polymorphic forms may be used in accordance with the present invention.
  • The sequence listing herein includes polymorphic forms of proteins 741 (SEQ IDs 1-22) and NMB 1343 (SEQ IDs 23-24) which have been identified.
  • Serogroups and Strains
  • Preferred proteins of the invention comprise —X— moieties having an amino acid sequence found in N. meningitidis serogroup B. Within a single protein of the invention, individual —X— moieties may be from one or more strains. Where n=2, for instance, X2 may be from the same strain as X1 or from a different strain. Where n=3, the strains might be (i) X1═X2═X3 (ii) X1═X2≠X3 (iii) X1≠X2═X3 (iv) X1≠X2≠X3 or (v) X1═X3≠X2, etc.
  • Within serogroup B, preferred —X— moieties are from strains 2996, MC58, 95N477, or 394/98. Strain 95N477 is sometimes referred to herein as ‘ET37’, this being its electrophoretic type. Strain 394/98 is sometimes referred to herein as ‘nz’, as it is a New Zealand strain.
  • Where a form of 287 is used, this is preferably from strain 2996 or from strain 394/98.
  • Where a form of 741 is used, this is preferably from serogroup B strains MC58, 2996, 394/98, or 95N477, or from serogroup C strain 90/18311.
  • Where a form of 961 is used, this is preferably from strain 2996.
  • Strains are indicated as a subscript e.g. 741MC58 is protein 741 from strain MC58. Unless otherwise stated, proteins mentioned herein (e.g. with no subscript) are from N. meningitidis strain 2996, which can be taken as a ‘reference’ strain. It will be appreciated, however, that the invention is not in general limited by strain. As mentioned above, general references to a protein (e.g. ‘287’, ‘919’ etc.) may be taken to include that protein from any strain. This will typically have sequence identity to 2996 of 90% or more (eg. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more).
  • Domain-Based Expression of Protein 961
  • References 1 and 2 disclose how a protein can be notionally divided into domains and how the protein can be manipulated based on these domains. The present invention extends the application of this approach to protein 961 (also known as ‘NadA’ [11,12]).
  • In N. meningitidis serogroup B strain 2996, NadA has 405 amino acids. This protein has notionally been divided into the following nine domains (FIG. 4):
  • Domain name Amino acids Domain name Amino acids
       961-1 ‘L’  1-23 961-6 269-286
    961-2 24-87 961-7 287-330
    961-3  88-143 961-8 331-350
    961-4 144-180 961-9 351-405
    961-5 181-268
  • This information can be used to locate the same domains in other forms of 961.
  • These domains have been deleted from 961 in strain 2996 in various ways (FIG. 5). Preferred fragments of 961 omit one or more of these nine domains e.g. the following:
      • 961-2 to 961-5 (‘961a’)
      • 961-6 to 961-9 (‘961b’)
      • 961-1 to 961-8 (‘961 cL’)
      • 961-2 to 961-8 (‘961c’)
      • 961-2 to 961-6 and amino acids 287-325 from domain 961-7 (‘961d’)
      • 961-2 to 961-8 and amino acids 351-383 from domain 961-9 (‘961Δ1’)
      • 961-1 to 961-8 and amino acids 351-383 from domain 961-9 (‘961Δ1L’)
      • 961-1 to 961-7 and amino acids 331-343 from domain 961-8 (‘961cL-Δaro’)
      • 961-1 to 961-6 and amino acids 287-315 from domain 961-7 (‘961cL-Δcc’)
      • 961-1 to 961-5 (‘961aL’)
      • 961-1 to 961-4 (‘961aL-Δ1’)
      • 961-1 to 961-3 (‘961aL-Δ2’)
      • 961-1 to 961-2 (‘961aL-Δ3’)
  • These thirteen fragments (and sub-fragments thereof missing 1, 2, 3, 4 or 5 amino acids at either or both ends) are preferred (c) and (j) fragments, but they may also be expressed in their own right i.e. not in the form of a hybrid protein of the invention. Thus the invention provides a protein comprising one of these fragments, providing that the protein is not full-length 961 and is not a protein specifically disclosed in reference 1 or 2. This protein may be a fusion protein (e.g. a GST-fusion or a His-tag fusion).
  • Sequences
  • The invention also provides a protein having an amino acid sequence from SEQ IDs 1 to 24. It also provides proteins and nucleic acid having sequence identity to these. As described above, the degree of ‘sequence identity’ is preferably greater than 50% (eg. 60%, 70%, 80%, 90%, 95%, 99% or more).
  • The invention also provides nucleic acid encoding such proteins.
  • Furthermore, the invention provides nucleic acid which can hybridise to this nucleic acid, preferably under “high stringency” conditions (eg. 65° C. in a 0.1×SSC, 0.5% SDS solution).
  • The invention also provides nucleic acid encoding proteins according to the invention.
  • It should also be appreciated that the invention provides nucleic acid comprising sequences complementary to those described above (eg. for antisense or probing purposes).
  • Nucleic acid according to the invention can, of course, be prepared in many ways (eg. by chemical synthesis, from genomic or cDNA libraries, from the organism itself etc.) and can take various forms (eg. single stranded, double stranded, vectors, probes etc.).
  • In addition, the term “nucleic acid” includes DNA and RNA, and also their analogues, such as those containing modified backbones, and also peptide nucleic acids (PNA) etc.
  • Mixtures
  • The invention also provides a composition comprising two or more (i.e. 2, 3, 4, 5, 6 or 7) of the following proteins:
      • (1) 287
      • (2) 741
      • (3) ORF46.1
      • (4) 961
      • (5) NH2-A-[—X-L-]n-B—COOH, wherein n=2, X1=287, X2=953
      • (6) NH2-A-[—X-L-]n-B—COOH, wherein n=2, X1=287, X2=919
      • (7) NH2-A-[—X-L-]n-B—COOH, wherein n=2, X1=287, X2=961
  • The mixture may include one or both of the following proteins, either in combination with two or more of (1) to (7), or in combination with only one of (1) to (7):
      • (8) NH2-A-[—X-L-]n-B—COOH, wherein n=2, X1=287, X2=741
      • (9) NH2-A-[—X-L-]n-B—COOH, wherein n=2, X1=936, X2=741
  • Where proteins 287 and 741 are included in the mixture (i.e. in protein 1, 2, 5, 6, 7 or 8), they may be in the ‘ΔG’ form. Where protein 961 is included, it is preferably in the form of ‘961c’ in which the N-terminus leader and C-terminus membrane anchor are absent [e.g. see refs. 1, 2 & 11].
  • A preferred mixture comprises the following three proteins:
      • (1) 961c, preferably 961c2996 (e.g. SEQ ID 31 herein);
      • (2) NH2-A-[—X-L-]n-B—COOH, wherein n is 2, —X1— is ΔG287 (preferably ΔG287NZ), —X2— is 953 (preferably 9532996) lacking its leader peptide, -L1- is GSGGGG, and -A- comprises a N-terminus methionine (e.g. -A- is M or MA) (e.g. SEQ IDs 28 & 29 herein); and
      • (3) NH2-A-[—X-L-]n-B—COOH, wherein n=2, X1=936 (preferably 9362996), X2=ΔG741 (preferably ΔG741 MC58), L1=GSGGGG (e.g. SEQ ID 30 herein).
  • The mixtures may also comprise N. meningitidis outer membrane vesicles.
  • Heterologous Host
  • Whilst expression of the proteins of the invention may take place in Neisseria, the present invention preferably utilises a heterologous host. The heterologous host may be prokaryotic (e.g. a bacterium) or eukaryotic. It is preferably E. coli, but other suitable hosts include Bacillus subtilis, Vibrio cholerae, Salmonella typhi, Salmonenna typhimurium, Neisseria lactamica, Neisseria cinerea, Mycobacteria (e.g. M. tuberculosis), yeast etc.
  • Vectors Etc.
  • The invention provides (a) nucleic acid encoding the proteins described above (b) vectors comprising these nucleic acid sequences (c) host cells containing said vectors (d) compositions comprising the proteins or nucleic acids of the invention, which may be suitable as immunogenic compositions (e.g. vaccines) or as diagnostic reagents (e) these compositions for use as medicaments (e.g. as vaccines) or as diagnostic reagents (f) the use of these compositions in the manufacture of (1) a medicament for treating or preventing infection due to Neisserial bacteria (2) a diagnostic reagent for detecting the presence of Neisserial bacteria or of antibodies raised against Neisseria bacteria, and/or (3) a reagent which can raise antibodies against Neisseria bacteria and (g) a method of treating a patient, comprising administering to the patient a therapeutically effective amount of these compositions.
  • Implementing the invention will typically involve the basic steps of: obtaining a first nucleic acid encoding a first protein; obtaining a second nucleic acid encoding a second protein; and ligating the first and second nucleic acids. The resulting nucleic acid may be inserted into an expression vector, or may already be part of an expression vector.
  • To improve solubility, purification of hybrid proteins may involve the refolding techniques disclosed herein.
  • Immunogenic Compositions and Medicaments
  • The compositions of the invention are preferably immunogenic composition, and are more preferably vaccine compositions. The pH of the composition is preferably between 6 and 7. The pH may be maintained by the use of a buffer. The composition may be sterile.
  • Vaccines according to the invention may either be prophylactic (i.e. to prevent infection) or therapeutic (i.e. to treat infection), but will typically be prophylactic.
  • The invention also provides a composition of the invention for use as a medicament. The medicament is preferably able to raise an immune response in a mammal (i.e. it is an immunogenic composition) and is more preferably a vaccine.
  • The invention also provides the use of a composition of the invention in the manufacture of a medicament for raising an immune response in a mammal. The medicament is preferably a vaccine.
  • The invention also provides a method for raising an immune response in a mammal comprising the step of administering an effective amount of a composition of the invention. The immune response is preferably protective. The method may raise a booster response.
  • The mammal is preferably a human. Where the vaccine is for prophylactic use, the human is preferably a child (e.g. a toddler or infant); where the vaccine is for prophylactic use, the human is preferably an adult. A vaccine intended for children may also be administered to adults e.g. to assess safety, dosage, immunogenicity, etc.
  • These uses and methods are preferably for the prevention and/or treatment of a disease caused by a Neisseria (e.g. meningitis, septicaemia, gonorrhoea etc.). The prevention and/or treatment of bacterial meningitis is preferred.
  • Further Components of the Composition
  • The composition of the invention will typically, in addition to the components mentioned above, comprise one or more ‘pharmaceutically acceptable carriers’, which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, trehalose (WO00/56365) and lipid aggregates (such as oil droplets or liposomes). Such carriers are well known to those of ordinary skill in the art. The vaccines may also contain diluents, such as water, saline, glycerol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences.
  • Immunogenic compositions used as vaccines comprise an immunologically effective amount of antigen, as well as any other of the above-mentioned components, as needed. By ‘immunologically effective amount’, it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (e.g. non-human primate, primate, etc.), the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. Dosage treatment may be a single dose schedule or a multiple dose schedule (e.g. including booster doses). The vaccine may be administered in conjunction with other immunoregulatory agents.
  • The vaccine may be administered in conjunction with other immunoregulatory agents.
  • The composition may include other adjuvants in addition to (or in place of) the aluminium salt. Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59™ (WO90/14837; Chapter 10 in ref. 13), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing MTP-PE) formulated into submicron particles using a microfluidizer, (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribi™ adjuvant system (RAS), (Ribi Immunochem, Hamilton, Mont.) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL+CWS (Detox™); (2) saponin adjuvants, such as QS21 or Stimulon™ (Cambridge Bioscience, Worcester, Mass.) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes), which ISCOMS may be devoid of additional detergent e.g. WO00/07621; (3) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (4) cytokines, such as interleukins (e.g. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 (WO99/44636), etc.), interferons (e.g. gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; (5) monophosphoryl lipid A (MPL) or 3-0-deacylated MPL (3dMPL) e.g. GB-2220221, EP-A-0689454; (6) combinations of 3dMPL with, for example, QS21 and/or oil-in-water emulsions e.g. EP-A-0835318, EP-A-0735898, EP-A-0761231; (7) oligonucleotides comprising CpG motifs [Krieg Vaccine 2000, 19, 618-622; Krieg Curr opin Mol Ther 2001 3:15-24; Roman et al., Nat. Med., 1997, 3, 849-854; Weiner et al., PNAS USA, 1997, 94, 10833-10837; Davis et al., J. Immunol., 1998, 160, 870-876; Chu et al., J. Exp. Med., 1997, 186, 1623-1631; Lipford et al., Eur. J. Immunol., 1997, 27, 2340-2344; Moldoveanu et al., Vaccine, 1988, 16, 1216-1224, Krieg et al., Nature, 1995, 374, 546-549; Klinman et al., PNAS USA, 1996, 93, 2879-2883; Ballas et al., J. Immunol., 1996, 157, 1840-1845; Cowdery et al., J. Immunol., 1996, 156, 4570-4575; Halpern et al., Cell. Immunol., 1996, 167, 72-78; Yamamoto et al., Jpn. J. Cancer Res., 1988, 79, 866-873; Stacey et al., J. Immunol., 1996, 157, 2116-2122; Messina et al., J. Immunol., 1991, 147, 1759-1764; Yi et al., J. Immunol., 1996, 157, 4918-4925; Yi et al., J. Immunol., 1996, 157, 5394-5402; Yi et al., J. Immunol., 1998, 160, 4755-4761; and Yi et al., J. Immunol., 1998, 160, 5898-5906; International patent applications WO96/02555, WO98/16247, WO98/18810, WO98/40100, WO98/55495, WO98/37919 and WO98/52581] i.e. containing at least one CG dinucleotide, with 5-methylcytosine optionally being used in place of cytosine; (8) a polyoxyethylene ether or a polyoxyethylene ester e.g. WO99/52549;
  • (9) a polyoxyethylene sorbitan ester surfactant in combination with an octoxynol (e.g. WO01/21207) or a polyoxyethylene alkyl ether or ester surfactant in combination with at least one additional non-ionic surfactant such as an octoxynol (e.g. WO01/21152); (10) an immunostimulatory oligonucleotide (e.g. a CpG oligonucleotide) and a saponin e.g. WO00/62800; (11) an immunostimulant and a particle of metal salt e.g. WO00/23105; (12) a saponin and an oil-in-water emulsion e.g. WO99/11241; (13) a saponin (e.g. QS21)+3dMPL+IL-12 (optionally+a sterol) e.g. WO98/57659; (14) other substances that act as immunostimulating agents to enhance the efficacy of the composition.
  • Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE), etc.
  • Further Antigens
  • Further antigens which can be included in the composition of the invention include:
      • an outer-membrane vesicle (OMV) preparation from N. meningitidis serogroup B, such as those disclosed in refs. 14, 15, 16, 17 etc.
      • a saccharide antigen from N. meningitidis serogroup A, C, W135 and/or Y, such as the oligosaccharide disclosed in ref. 18 from serogroup C [see also ref. 19] or the oligosaccharides of ref. 20.
      • a saccharide antigen from Streptococcus pneumoniae [e.g. refs. 21, 22, 23].
      • a protein antigen from Helicobacter pylori such as CagA [e.g. 24], VacA [e.g. 24], NAP [e.g. 25], HopX [e.g. 26], HopY [e.g. 26] and/or urease.
      • an antigen from hepatitis A virus, such as inactivated virus [e.g. 27, 28].
      • an antigen from hepatitis B virus, such as the surface and/or core antigens [e.g. 28, 29].
      • an antigen from hepatitis C virus [e.g. 30].
      • an antigen from Bordetella pertussis, such as pertussis holotoxin (PT) and filamentous haemagglutinin (FHA) from B. pertussis, optionally also in combination with pertactin and/or agglutinogens 2 and 3 [e.g. refs. 31 & 32].
      • a diphtheria antigen, such as a diphtheria toxoid [e.g. chapter 3 of ref. 33] e.g. the CRM197 mutant [e.g. 34].
      • a tetanus antigen, such as a tetanus toxoid [e.g. chapter 4 of ref. 33].
      • a saccharide antigen from Haemophilus influenzae B [e.g. 19].
      • an antigen from N. gonorrhoeae [e.g. 3, 4, 5].
      • an antigen from Chlamydia pneumoniae [e.g. 35, 36, 37, 38, 39, 40, 41].
      • an antigen from Chlamydia trachomatis [e.g. 42].
      • an antigen from Porphyromonas gingivalis [e.g. 43].
      • polio antigen(s) [e.g. 44, 45] such as IPV or OPV.
      • rabies antigen(s) [e.g. 46] such as lyophilised inactivated virus [e.g.47, RabAvert™]
      • measles, mumps and/or rubella antigens [e.g. chapters 9, 10 & 11 of ref. 33].
      • influenza antigen(s) [e.g. chapter 19 of ref. 33], such as the haemagglutinin and/or neuraminidase surface proteins.
      • an antigen from Moraxella catarrhalis [e.g. 48].
      • a protein antigen from Streptococcus agalactiae (group B streptococcus) [e.g. 49, 50].
      • a saccharide antigen from Streptococcus agalactiae
      • an antigen from Streptococcus pyogenes (group A streptococcus) [e.g. 50, 51, 52].
      • an antigen from Staphylococcus aureus [e.g. 53].
  • The composition may comprise one or more of these further antigens.
  • Where a saccharide or carbohydrate antigen is used, it is preferably conjugated to a carrier protein in order to enhance immunogenicity [e.g. refs. 54 to 63]. Preferred carrier proteins are bacterial toxins or toxoids, such as diphtheria or tetanus toxoids. The CRM197 diphtheria toxoid is particularly preferred. Other suitable carrier proteins include the N. meningitidis outer membrane protein [e.g. ref. 64], synthetic peptides [e.g. 65, 66], heat shock proteins [e.g. 67], pertussis proteins [e.g. 68, 69], protein D from H. influenzae [e.g. 70], toxin A or B from C. difficile [e.g. 71], etc. Where a mixture comprises capsular saccharides from both serogroups A and C, it is preferred that the ratio (w/w) of MenA saccharide:MenC saccharide is greater than 1 (e.g. 2:1, 3:1, 4:1, 5:1, 10:1 or higher). Saccharides from different serogroups of N. meningitidis may be conjugated to the same or different carrier proteins.
  • Any suitable conjugation reaction can be used, with any suitable linker where necessary.
  • Toxic protein antigens may be detoxified where necessary (e.g. detoxification of pertussis toxin by chemical and/or genetic means [32]).
  • Where a diphtheria antigen is included in the composition it is preferred also to include tetanus antigen and pertussis antigens. Similarly, where a tetanus antigen is included it is preferred also to include diphtheria and pertussis antigens. Similarly, where a pertussis antigen is included it is preferred also to include diphtheria and tetanus antigens.
  • Antigens are preferably mixed with (and more preferably adsorbed to) an aluminium salt (e.g. phosphate, hydroxide, hydroxyphosphate, oxyhydroxide, orthophosphate, sulphate). The salt may take any suitable form (e.g. gel, crystalline, amorphous etc.).
  • Antigens in the composition will typically be present at a concentration of at least 1μg/ml each. In general, the concentration of any given antigen will be sufficient to elicit an immune response against that antigen.
  • As an alternative to using proteins antigens in the composition of the invention, nucleic acid encoding the antigen may be used [e.g. refs. 72 to 80]. Protein components of the compositions of the invention may thus be replaced by nucleic acid (preferably DNA e.g. in the form of a plasmid) that encodes the protein.
  • Definitions
  • The term “comprising” means “including” as well as “consisting” e.g. a composition “comprising” X may consist exclusively of X or may include something additional e.g. X+Y.
  • The term “about” in relation to a numerical value x means, for example, x±10%.
    • BRIEF DESCRIPTION OF DRAWINGS
  • FIG. 1 shows an alignment of twenty-three sequences for protein 741. These are SEQ IDs 1 to 22 plus the sequence from MC58.
  • FIG. 2 shows an alignment of the NMB 1343 sequence from gonococcus (top; SEQ ID 25) and meningococcus (bottom; SEQ ID 26).
  • FIG. 3 shows hybrid and tandem proteins of the invention.
  • FIG. 4 shows 9 domains within 9612996, and FIG. 5 shows how these have been manipulated.
    •  MODES FOR CARRYING OUT THE INVENTION
  • Hybrid Proteins—X1=ΔG287
  • In addition to those disclosed in references 1 & 2, seven hybrid proteins with ΔG287 from strain 2996 at the N-terminus were constructed. Eight 287 tandem proteins were also made (see below).
  • # n X1 L1 X2 L2
    1 2 ΔG287 — 230 (His)6
    2 2 — 936 (His)6
    3 2 — 741MC58 (His)6
    4 2 — 741ET37 (His)6
    5 2 — 74190/18311 (His)6
    6 2 — 74195N477 (His)6
    7 2 ΔG287nz — 741MC58 (His)6
  • These proteins were adjuvanted with either Freund's complete adjuvant (FCA) or 3 mg/ml alum and used to immunise mice. The resulting sera were tested against various Neisserial strains using the bactericidal assay. Titres using protein #3 were as follows:
  • Strain(serogroup)
    2996(B) MC58(B) NGH38(B) 394/98(B) 44/76(B) F6124(A)
    Al hydroxide 8192 32768 8192 >2048 16384 8192
    FCA 16384 262144 8192 >2048 >32768 8192
  • In further experiments using protein #3 adjuvanted with aluminium hydroxide, anti-287 and anti-741 ELISA titres each exceeded 984150 and BCA titres were as follows:
  • 2996(B) MC58(B) NGH38(B) 394/98(B) 44/76(B) F6124(A) BZ133(C)
    8000 65000 4000 4000 32000 8000 16000
  • Results obtained after immunisation with proteins disclosed in refs. 1 & 2, tested against the homologous strain, were as follows:
  • Bactericidal
    titre ELISA
    n X1 L1 X2 L2 FCA Alum FCA Alum
    2 ΔG287394/98 — 961 (His)6 — 32768 — >109350
    919 32768 4096 4718 3678
    953 >32768 >16384 1900 6936
    741 16384 2048 232 862
    2 ΔG2872996 — 961 (His)6 65536 32768 108627 >109350
    919 128000 32000 11851 2581
    953 65536 — 3834 —
    741 16384 8192 315 4645
  • Hybrid Proteins—X1=961c or 961cL
  • In addition to those disclosed in references 1 & 2, eight hybrid proteins with either 961c or 961cL (i.e. 961c+leader peptide) at the N-terminus were constructed:
  • # n X1 L1 X2 L2
    1 2 961c — 287 —
    2 2 — 287 (His)6
    3 2 — 230 (His)6
    4 2 — 936 (His)6
    5 2 961cL — 287 —
    6 2 — 287 (His)6
    7 2 — 230 (His)6
    8 2 — 936 (His)6
  • These proteins were adjuvanted with either Freund's complete adjuvant (FCA) or 3.3 mg/ml alum and used to immunise mice. The resulting sera were tested against various Neisserial strains using the bactericidal assay. Titres using protein #8 were as follows:
  • Strain(serogroup) 2996(B) MC58(B) 394/98(B) 44/76(B) F6124(A)
    Al hydroxide 8192 8192 512 1024 <16
    FCA 65536 16384 >2048 >2048 8192
  • Titres obtained after immunisation with 961c-741 [refs. 1 & 2] were as follows:
  • Strain(serogroup)
    2996(B) MC58(B) 394/98(B) 44/76(B) F6124(A) BZ133(C)
    Al hydroxide 65536 32768 4096 >32768 16384 >2048
    FCA >16384 262144 4096 >16384 — >2048
  • These results could be improved by mixing 961c-741 with ORF46.1 or with ΔG287-919.
  • Results obtained after immunisation with proteins disclosed in refs. 1 & 2, tested against the homologous strain, were as follows:
  • Bactericidal
    titre ELISA
    n X1 L1 X2 L2 FCA Alum FCA Alum
    2 961c — ORF46.1 (His)6 32768 1024 >109350 >109350
    741 >16384 8192 >109350 >109350
    936 >32768 8192 >109350 >109350
  • Hybrid Proteins—X1=ORF46.1
  • In addition to those disclosed in references 1 & 2, two hybrid proteins with ORF46.1 at the N-terminus were constructed:
  • # n X1 L1 X2 L2
    1 2 ORF46.1 — 936 (His)6
    2 2 — 230 (His)6
  • These proteins were adjuvanted with either Freund's complete adjuvant (FCA) or 3 mg/ml alum and used to immunise mice. The resulting sera were tested against the homologous strain using the bactericidal assay and by ELISA.
  • Results obtained after immunisation with proteins disclosed in refs. 1 & 2 were as follows:
  • Bacteri-
    cidal
    titre ELISA
    n X1 L1 X2 L2 FCA Alum FCA Alum
    2 ORF46.1 — 961 (His)6 8192 8192 21558 >109350
    — 961c (His)6 8192 128 9020 76545
  • Hybrid Proteins—X1=230
  • In addition to those disclosed in references 1 & 2, four hybrid proteins with 230 at the N-terminus were constructed:
  • # n X1 L1 X2 L2
    1 2 230 — ORF46.1 (His)6
    2 2 — 961 (His)6
    3 2 — 961c (His)6
    4 2 — 741MC58 (His)6
  • Hybrid Proteins—Xj=936
  • In addition to those disclosed in references 1 & 2, seven hybrid proteins with 936 at the N-terminus were constructed:
  • # n X1 L1 X2 L2
    1 2 936 — ORF46.1 (His)6
    2 2 — 961 (His)6
    3 2 — 741ET37 (His)6
    4 2 — 741MC58 (His)6
    5 2 — 74190/18311 (His)6
    6 2 — 74195N477 (His)6
    7 2 — 741 (His)6
  • These proteins were adjuvanted with either Freund's complete adjuvant (FCA) or 3 mg/ml alum and used to immunise mice. The resulting sera were tested against various Neisserial strains using the bactericidal assay. Titres using protein #2 were as follows:
  • Strain(serogroup) 2996(B) MC58(B) 394/98(B) 44/76(B) F6124(A)
    Al hydroxide 16384 32768 1024 2048 <16
    FCA 65536 65536 >2048 8192 2048 (36%)
  • Titres using protein #4 were as follows:
  • Strain(serogroup) 2996(B) MC58(B) 394/98(B) 44/76(B) F6124(A)
    Al hydroxide 256 >262144 >2048 32768 8192
    FCA 1024 >262144 >2048 >32768 >32768
  • Titres using protein #7 were as follows:
  • Strain(serogroup)
    2996(B) MC58(B) 394/98(B) 44/76(B) F6124(A) BZ133(C)
    Al hydroxide 256 130000 16000 32000 8000 16000
  • Results obtained after immunisation with proteins disclosed in refs. 1 & 2, tested against the homologous strain, were as follows:
  • Bactericidal
    titre ELISA
    n X1 L1 X2 L2 FCA Alum FCA Alum
    2 936 — 741 (His)6 1024 256 1466 5715
    936 >32768 >32768 >109350 >109350
  • Mixtures of Hybrid Proteins
  • Mice were immunised with of three proteins adjuvanted with aluminium hydroxide, either single or in a triple combination: (1) 287NZ-953; (2) 936-741; and (3) 961c. The mixture was able to induce high bactericidal titres against various strains:
  • 2996(B) MC58(B) NGH38 394/98(B) H44/76(B) F6124(A) BZ133(C) C11(C)
    (1) 32000 16000 130000 16000 32000 8000 16000 8000
    (2) 256 131000 128 16000 32000 8000 16000 <4
    (3) 32000 8000 — — — 8000 — 32000
    mix 32000 32000 65000 16000 260000 65000 >65000 8000
    (X) 4000 4000 1000 1000 >4000 1000 4000 n.d.
    ‘—’ indicates that this strain contains no NadA gene
    (X) was a combination of protein 287 with outer membrane vesicles, for comparison
  • Looking at individual mice, the mixture induced high and consistent bactericidal titres:
  • #
    1 2 3 4 5 6 7 8 9 10
    2996 32768 16384 65536 32768 32768 65536 65536 32768 65536 8192
    MC58 65536 32768 65536 65536 65536 8192 65536 32768 32768 65536
    394/98 65536 4096 16384 4096 8192 4096 32768 16384 8192 16384
  • Tandem Proteins
  • Hybrid proteins of the invention can be represented by formula NH2—[—X-L-]n-COOH. Where all n instances of —X— are the same basic protein (either identical, or the same protein from different strains or species), the protein is referred to as a ‘tandem’ protein.
  • Twelve specific tandem proteins are:
  • # n X1 L1 X2 L2
    1 2 ΔG741MC58 — 741MC58 (His)6
    2 2 ΔG2872996 (Gly)6 ΔG287394/98 (His)6
    3 2 ΔG2872996 (Gly)6 ΔG2872996 (His)6
    4 2 ΔG287394/98 (Gly)6 ΔG287394/98 (His)6
    5 2 ΔG287394/98 (Gly)6 ΔG2872996 (His)6
    6 2 ΔG2872996 (Gly)6 ΔG287394/98 —
    7 2 ΔG2872996 (Gly)6 ΔG2872996 —
    8 2 ΔG287394/98 (Gly)6 ΔG287394/98 —
    9 2 ΔG287394/98 (Gly)6 ΔG2872996 —
    10 2 ΔG741MC58 — 741394/98 (His)6
    11 2 ΔG741MC58 — 74190/18311 (His)6
    12 2 ΔG741MC58 — 74195N477 (His)6
  • Proteins #1 to #5 have all been expressed in soluble form in E. coli. Expression levels were between 0.24 and 0.50 mg protein per litre of culture. The tandem proteins were purified and mixed with aluminium phosphate as an adjuvant. Tandem proteins #2, #4 and #5 adsorbed readily to aluminium phosphate; adsorption was less complete for tandem proteins #1 and #3.
  • Allelic Variants—741
  • Twenty-two polymorphic sequences of 741 were found (SEQ IDs 1 to 22). These and the MC58 sequence are aligned in FIG. 1.
  • Allelic Variants—NMB1343
  • Using PCR on 42 strains of meningococcus of various serogroups, the gene encoding NMB1343 protein was found in 24/42 and was absent in 18/42 strains (Table 1). The NMB gene was sequenced for 10 of the NMB1343+ strains (Table 1, column 3). The nucleic acid sequence (and thus amino acid sequence SEQ ID 23; GenBank AAF41718) was identical in all 10 strains.
  • NMB1343 was also detected in two strains of N. gonorrhoeae (F62 and SN4). The amino acid sequence from gonococcus is SEQ ID 24. An alignment with the meningococcal sequence is:
  • Figure US20150273044A1-20151001-C00001
  • An alignment of the corresponding nucleotide sequences is shown in FIG. 2. This shows that the gonococcal sequence has a 4 mer insertion in the 5′ region of the NMB1343 gene which causes a frameshift and consequent loss of the 5′ methionine residue.
  • Domain Deletion—961
  • 961 is not present in the N. meningitidis serogroup A genome sequence [81], even though the surrounding regions are conserved (>90%) between serogroups A and B. References 11 and 12 disclose polymorphic forms of 961. The gene was found to be present in 91% of serogroup B strains belonging to hypervirulent lineages ET-5, ET-37 and cluster A4, but was absent in all strains of lineage 3 tested. Most of the serogroup C strains tested were positive even if not belonging to hypervirulent lineages. The same was true for the serogroup B strains with serotype 2a and 2b. For serogroup A, one strain belonging to subgroup III was positive whereas the other two strains belonging to subgroup IV-1 were negative. 961 was absent in N. gonorrhoeae and in commensal species N. lactamica and N. cinerea.
  • FIGS. 4 and 5 show domains in protein 961.
  • When the anchor region (domain 9) of protein 961 is deleted (‘961cL’) and expressed in E. coli, the protein is exported in the periplasm and secreted in the supernatant of the culture.
  • To investigate this further, deletion mutants in the C-terminal region of 961 were constructed (961cL-Δaro, 961cLΔcc, 961aL, 961aL-Δ1, 961aL-Δ2, 961aL-Δ3) on the basis of structural features (deletions of aromatic residues in the cases of 961cΔaro mutant, and of coiled-coil regions for the others). These were analysed for expression and secretion into the periplasm and the supernatant of the culture. In all of these deletion mutants, the protein is produced in large amount, is present in periplasmic fraction, and is released in the supernatant of the culture.
  • ΔG287—Cross-Strain Bactericidal Activity
  • 287 was cloned for five different N. meningitidis serogroup B strains and was manipulated to delete the N-terminus up to the end of the poly-glycine region and to introduce a C-terminal his-tag. This gave five ΔG287 proteins. These were adjuvanted with FCA and used to raise immune sera in mice, which were then tested for bactericidal activity against all five serogroup B strains and also against serogroup A and C strains. Bactericidal titres were as follows:
  • Protein Sera tested for bactericidal activity against strain*
    strain 2996 BZ232 MC58 1000 394/98 F6124 BZ133
    2996 16000 128 4096 4096 1024 8000 16000
    BZ232 >8000 256 2048 8000 2048 16000 8000
    MC58 >8000 64 >8000 8000 2048 8000 8000
    1000 >8000 64 4096 8000 1024 16000 16000
    394/98 >16000 128 16000 >2048 >16000 — —
    *titres against homologous strain shown in bold
  • Refolding
  • To improve the levels of soluble protein for some hybrid proteins, alternative refolding protocols to those disclosed in reference 2 were adopted.
  • Inclusion Bodies (IBs) Were Isolated as Follows:
      • 1. Homogenize cells (5 g wet weight) in 25 ml 0.1 M Tris- HCl pH 7, 1 mM EDTA, at 4° C. using an ultraturrax (10 000 rpm)
      • 2. Add 1.5 mg lysozyme per gram cells, mix shortly with an ultraturrax, and incubate at 4° C. for 30 min.
      • 3. Use sonication or high-pressure homogenization (French press) to disrupt the cells.
      • 4. To digest DNA, add MgCl2 to a final concentration of 3 mM and DNase to a final concentration of 10 μg/ml, and incubate for 30 min at 25° C.
      • 5. Add 0.5 vol. 60 mM EDTA, 6% Triton X-100, 1,5M NaCl pH7, to the solution, and incubate for 30 min at 4° C.
      • 6. Spin down inclusion bodies by centrifugation at 31000 g (20 000 rpm) for 10 min, 4° C.
      • 7. Resuspend pellet in 40 ml 0.1 M tris- HCl pH 7, 20 mM EDTA, using an ultraturrax
      • 8. Repeat centrifugation step 6.
      • 9. The inclusion body pellet may be used, or stored frozen at −20° C.
  • Hybrid proteins were expressed in E. coli as follows:
  • Culture Flask Inclusion
    volume volume Temp Final body yield
    Protein (liters) (liters) (° C.) OD600 (w/w)
    ORF46.1-961-His 1 2 37 1.51 33.2%
    ORF46.1-961c-His 1 2 37 1.6 28.3%
    961c-ORF46.1His 1 2 37 1.18 23.5%
    orf46.1-741 His 5 5 37 12.42 35.2
  • The pellets were solubilised, refolded, ultrafiltered, dialysed, and protein was then purified:
  • ORF46.1-961-His IBs were solubilised as follows: IB proteins were resuspended in 4 ml of 6M guanidine HCl, 1 mM EDTA pH 8.5 buffer, to a final protein concentration of 1 mg/ml. To refold the protein, 2 ml of solubilised protein was diluted in 400 ml of refolding buffer (0.1M Tris HCl, 1M L-arginine, 2 mM EDTA pH 8.2) and incubated for 1 hour at 15° C., resulting in a protein concentration of 5 μg/ml. Subsequently, another 2 ml of the solubilised protein was added and incubated for an additional hour at the same temperature resulting in a final protein concentration of 10 μg/ml. The material was ultrafiltered using a 300 ml Amicon ultrafiltration cell (8400), applying a 3 bar pressure on an Amicon membrane with a 30 kDa cut-off (YM30) resulting in 130 ml final volume. The ultrafiltered material was dialysed using a regenerated cellulose tubular membrane with a 12-14 kDa cutoff (Cellusep—Step bio) for 24 hours against 10 L of 0.1M Tris HCl pH 8.2 buffer. A second dialysis of 24 h against 10 L of 300 mM NaCl, 50 mM sodium phosphate pH 8.0 buffer was performed. The dialysed material was centrifuged at 22000 rpm for 45 minutes at 4° C. in a Beckman centrifuge rotor JA25.5 The supernatant isolated after centrifugation was used for His-tag purification.
  • orf 46.1-961c-His IBs were solubilised as follows: IB proteins were resuspended in 4 ml of 6M guanidine HCl, 1 mM EDTA pH 8.5 buffer, to a final protein concentration of 1 mg/ml. To refold the protein, 2 ml of the solubilised protein was diluted in 400 ml refolding buffer (0.5M Tris HCl, 1M L-arginine, 2 mM EDTA pH 8.2) and incubated for 1 h at 15° C., resulting in a protein concentration of 5 μg/ml. Subsequently another 2 ml of the solubilised protein was added and incubated for an additional hour at the same temperature resulting in a final protein concentration of 10 μg/ml. The material was ultrafiltered using a 300 ml Amicon ultrafiltration cell (8400), applying a 3 bar pressure on an Amicon membrane with a 30 kDa cut-off (YM30) resulting in 150 ml final volume. The ultrafiltered material was dialysed using a regenerated cellulose tubular membrane with a 12-14 kDa cutoff (Cellusep—Step bio) for 24 h against 10 L of 0.1M Tris HCl pH 8.2 buffer. A second dialysis of 24 h against 10 L of 300 mM NaCl, 50 mM sodium phosphate pH 8.0 buffer was performed. The dialysed material was centrifuged at 22000 rpm for 45 minutes at 4° C. in a Beckman centrifuge rotor JA25.5. The supernatant isolated after centrifugation was used for His-tag purification.
  • 961c-orf46.1-His IBs were solubilised as follows: IB proteins were resuspended in 4 ml of 6M guanidine HCl, 1 mM EDTA pH 8.5 buffer, to a final protein concentration of 1 mg/ml. To refold the protein, 2 ml of the solubilised protein was diluted in 400 ml refolding buffer (0.1M Tris HCl, 0.5 M L-arginine,2 mM EDTA pH 8.2) and incubated for 1 h at 15° C., resulting in a protein concentration of 5 μg/ml. Subsequently another 2 ml of the solubilized protein was added and incubated for an additional hour at the same temperature resulting in a final protein concentration of 10 μg/ml. The material was ultrafiltered using a 300 ml Amicon ultrafiltration cell (8400), applying a 3 bar pressure on an Amicon membrane with a 30 kDa cut-off (YM30) resulting in 150 ml final volume. The ultrafiltered material was dialysed using a regenerated cellulose tubular membrane with a 12-14 kDa cutoff (Cellusep—Step bio) for 24 h against 10 L of 0.1 M Tris HCl pH 8.2 buffer. A second dialysis of 24 h against 10 L of 300 mM NaCl, 50 mM sodium phosphate pH 8.0 buffer was performed. The dialysed material was centrifuged at 22000 rpm for 45 minutes at 4° C. in a Beckman centrifuge rotor JA25.5. The supernatant isolated after centrifugation was used for His-tag purification.
  • orf46.1-741-His IBs were solubilised as follows: IB proteins were resuspended in 4 ml of 6M guanidine HCl, 1 mM EDTA pH 8.5 buffer, to a final protein concentration of 10 mg/ml. To refold, 2 ml of the solubilised protein was diluted in 400 ml of the refolding buffer (0.5M Tris HCl, 0.7 M L-arginine, 2 mM EDTA pH 7.2) and incubated for 1 h at 15° C., resulting in a protein concentration of 50 μg/ml. Subsequently another 2 ml of the solubilised protein was added and incubated for an additional hour at the same temperature resulting in a final protein concentration of 100 μg/ml. The material was ultrafiltered using a 300 ml Amicon ultrafiltration cell (8400), applying a 3 bar pressure on an Amicon membrane with a 30 kDa cut-off (YM30) resulting in 120 ml final volume. The ultrafiltered material was dialysed using a regenerated cellulose tubular membrane with a 12-14 kDa cutoff (Cellusep—Step bio) for 24 h against 10 L of 0.1M Tris HCl pH 8.2 buffer. A second dialysis of 24 h against 10 L of 300 mM NaCl, 50 mM sodium phosphate pH 8.0 buffer was performed. The dialysed material was centrifuged at 22000 rpm for 45 minutes at 4° C. in a Beckman centrifuge rotor JA25.5 The supernatant isolated after centrifugation was used for His-tag purification.
  • Compared with proteins purified as described in ref. 2, bactericidal assay titres were as follows:
  • Reference 2 Refolded
    Alumin- Alumin- Alumin-
    ium ium ium
    hydrox- hydrox- phos-
    Protein CFA ide ide MF59 phate
    ORF46.1-961-His 8192 8192 32768 — —
    ORF46.1-961c-His 8192 128 <64 8192 —
    961c-ORF46.1His 32768 1024 16384 — —
    orf46.1-741 His <4 16 <4  256 —
  • Similar procedures were used for ORF46.1 to purify the protein from IBs when expressed with no His-tag (‘ORF46.1K’):
  • Culture Flask Inclusion
    volume volume Temp Final body yield
    Protein (liters) (liters) (° C.) OD600 (w/w)
    orf46.1K 5 5 37 13.7 29.4
  • IB proteins were resuspended in 4 ml of 6M guanidine HCl, 1 mM EDTA pH 8.5 buffer, to a final protein concentration of 10 mg/ml. To refold, 2 ml of the solubilised protein was diluted in 400 ml of the refolding buffer (0.5M Tris HCl, 0.7 M L-arginine,2 mM EDTA pH 7.2) and incubated for 1 hours at 15° C., resulting in a protein concentration of 50μg/ml. Subsequently another 2 ml of the solubilised protein was added and incubated for an additional hour at the same temperature resulting in a final protein concentration of 100 m/ml. The material was ultrafiltered using a 300 ml Amicon ultrafiltration cell (8400), applying a 3 bar pressure on an Amicon membrane with a 30 kDa cut-off (YM30) resulting in 120 ml final volume. The ultrafiltered material was dialysed using a regenerated cellulose tubular membrane with a 12-14 kDa cutoff (Cellusep—Step bio) for 12 h against 10 L of 50 mM sodium phosphate, 2 mM EDTA, pH 7.2 buffer. A second dialysis of 24 h against 10 L of the same buffer was performed. The dialysed material was centrifuged at 22000 rpm for 45 minutes at 4° C. in a Beckman centrifuge rotor JA25.5. The supernatant isolated after centrifugation was used for cationic exchange chromatography. The purification was done on a AKTA explorer chromatography system (Amersham-Pharmacia Biotech) using a 5 ml HiTrap SP sepharose HP column (Amersham-Pharmacia Biotech). The flow rate applied was of 1.5 ml per minute. The column was washed with 35 ml of 50 mM sodium phosphate buffer pH 7.2. A linear gradient (0-1 M NaCl) was performed using a 50 mM sodium phosphate buffer pH 7.2. The protein eluted in two peaks at 92 mM and 380 mM NaCl. The fractions constituting each peak were pooled and respectively named pool 1 and pool 2.
  • Compared with proteins purified as described in ref. 2, bactericidal assay titres when adjuvanted with aluminium hydroxide were improved from <4 to 1024. The titre using aluminium phosphate adjuvant with the refolded protein was 2048. ELISA titres were as follows:
  • Elisa SBA
    Protein Aluminium adjuvant (M7) (2996)
    Orf46.1k (pool 1) Hydroxide 3.3 mg/ml 1212 512
    Phosphate 0.6 mg/ml 154 1024
    Orf46.1k (pool 2) Hydroxide 3.3 mg/ml 1085 1024
    Phosphate 0.6 mg/ml 250 1024
  • It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.
  • TABLE 1
    Strain 1343 Sequence Strain classification
    72/00 + ET5 B:15:P1.7, 13, 13a
    30/00 + ET5 B:15:P1.7, 16
    39/99 + ET5 C:15:P1.7, 16
    95330 + ET5 B:4:P1.15
    M4102 + ET5 nd
    MC58(21) + + ET5 B:15:P1.7, 16b
    BZ169(7) + + ET5 B:NT:P1.16
    BZ83(19) + ET5 B:15:—.—
    CU385 + + ET5 B:4:P1.15
    220173I + ET5 NG:4:P1.15
    64/96 + + ET5 NG:15:P1.7, 16 (carrier)
    220173I + ET5 B:4:P1.15 (carrier)
    ISS1071 + nd B:15:P1.7, 16 (ET5?)
    BZ198(2) + + lin.3 B:8:P1.1
    980-2543 + + lin.3 B:NT:P1.4
    16060 + + other B:4:P1.14 (carrier)
    394-98 + nd B:4:P1.4 (lin 3?)
    ISS1106 + nd B:4:P1.4 (lin.3?)
    BZ133(10) + + sub I B:NT:—.—
    S3446 + + nd B:14:P1.23, 14
    ISS1001 + + nd B:14:P1.13
    241175I + other NG:21:P1.16 (carrier)
    171274I + other NG:15:— (carrier)
    66/96 + other B:17:P1.15 (carrier)
    961-5945 − A4
    96217 − A4
    312294 − A4
    90/18311(24) − ET37
    93/4286(25) − ET37
    M986 − ET37
    1000(5) − other
    NGE28(13) − other carrier
    NGH38(14) − other carrier
    BZ232(18) − other
    F6124(23) − sub III A:—.—
    C11 − C:—
    NMB − nd
    8047 − nd
    ISS759 − nd C:2b:P1.2
    ISS1113 − nd C:2:P1.5
    65/96 − nd 4:P1.14
    2996(96) − nd B:2b:P1.5, 2
    • REFERENCES (THE CONTENTS OF WHICH ARE HEREBY INCORPORATED BY REFERENCE)
    • 1—International patent application WO01/64920.
    • 2—International patent application WO01/64922.
    • 3—International patent application WO99/24578.
    • 4—International patent application WO99/36544.
    • 5—International patent application WO99/57280.
    • 6—International patent application WO00/22430.
    • 7—Tettelin et al. (2000) Science 287:1809-1815.
    • 8—International patent application WO00/66741.
    • 9—International patent application WO00/71574.
    • 10—International patent application WO01/04316
    • 11—International patent application PCT/IB02/03396.
    • 12—Comanducci et al. (2002) J Exp Med 195:1445-1454.
    • 13—Vaccine Design: subunit & adjuvant approach (1995) Powell & Newman (ISBN: 030644867X).
    • 14—International patent application WO01/52885.
    • 15—Bjune et al. (1991) Lancet 338(8775):1093-1096.
    • 16—Fukasawa et al. (1999) Vaccine 17:2951-2958.
    • 17—Rosenqvist et al. (1998) Dev. Biol. Stand. 92:323-333.
    • 18—Costantino et al. (1992) Vaccine 10:691-698.
    • 19—Costantino et al. (1999) Vaccine 17:1251-1263.
    • 20—International patent application PCT/IB02/03191.
    • 21—Watson (2000) Pediatr Infect Dis J 19:331-332.
    • 22—Rubin (2000) Pediatr Clin North Am 47:269-285, v.
    • 23—Jedrzejas (2001) Microbiol Mol Biol Rev 65:187-207.
    • 24—International patent application WO93/18150.
    • 25—International patent application WO99/53310.
    • 26—International patent application WO98/04702.
    • 27—Bell (2000) Pediatr Infect Dis J 19:1187-1188.
    • 28—Iwarson (1995) APMIS 103:321-326.
    • 29—Gerlich et al. (1990) Vaccine 8 Suppl:S63-68 & 79-80.
    • 30—Hsu et al. (1999) Clin Liver Dis 3:901-915.
    • 31—Gustafsson et al. (1996) N. Engl. J. Med. 334:349-355.
    • 32—Rappuoli et al. (1991) TIBTECH 9:232-238.
    • 33—Vaccines (1988) eds. Plotkin & Mortimer. ISBN 0-7216-1946-0.
    • 34—Del Guidice et al. (1998) Molecular Aspects of Medicine 19:1-70.
    • 35—International patent application WO02/02606.
    • 36—Kalman et al. (1999) Nature Genetics 21:385-389.
    • 37—Read et al. (2000) Nucleic Acids Res 28:1397-406.
    • 38—Shirai et al. (2000) J. Infect. Dis. 181(Suppl 3):S524-S527.
    • 39—International patent application WO99/27105.
    • 40—International patent application WO00/27994.
    • 41—International patent application WO00/37494.
    • 42—International patent application WO99/28475.
    • 43—Ross et al. (2001) Vaccine 19:4135-4142.
    • 44—Sutter et al. (2000) Pediatr Clin North Am 47:287-308.
    • 45—Zimmerman & Spann (1999) Am Fam Physician 59:113-118, 125-126.
  • 46—Dreesen (1997) Vaccine 15 Suppl:S2-6.
  • 47—MMWR Morb Mortal Wkly Rep 1998 Jan. 16; 47(1):12, 19.
    • 48—McMichael (2000) Vaccine 19 Suppl 1:S101-107.
    • 49—Schuchat (1999) Lancet 353(9146):51-6.
    • 50—WO02/34771.
    • 51—Dale (1999) Infect Dis Clin North Am 13:227-43, viii.
    • 52—Ferretti et al. (2001) PNAS USA 98: 4658-4663.
    • 53—Kuroda et al. (2001) Lancet 357(9264):1225-1240; see also pages 1218-1219.
    • 54—Ramsay et al. (2001) Lancet 357(9251):195-196.
    • 55—Lindberg (1999) Vaccine 17 Suppl 2:S28-36.
    • 56—Buttery & Moxon (2000) J R Coll Physicians Lond 34:163-168.
    • 57—Ahmad & Chapnick (1999) Infect Dis Clin North Am 13:113-133, vii.
    • 58—Goldblatt (1998) J. Med. Microbiol. 47:563-567.
  • 59—European patent 0 477 508.
    • 60—U.S. Pat. No. 5,306,492.
    • 61—International patent application WO98/42721.
    • 62—Conjugate Vaccines (eds. Cruse et al.) ISBN 3805549326, particularly vol. 10:48-114.
    • 63—Hermanson (1996) Bioconjugate Techniques ISBN: 0123423368 or 012342335X.
    • 64—European patent application 0372501.
    • 65—European patent application 0378881.
    • 66—European patent application 0427347.
    • 67—International patent application WO93/17712.
    • 68—International patent application WO98/58668.
    • 69—European patent application 0471177.
    • 70—International patent application WO00/56360.
    • 71—International patent application WO00/61761.
    • 72—Robinson & Torres (1997) Seminars in Immunology 9:271-283.
    • 73—Donnelly et al. (1997) Annu Rev Immunol 15:617-648.
    • 74—Scott-Taylor & Dalgleish (2000) Expert Opin Investig Drugs 9:471-480.
    • 75—Apostolopoulos & Plebanski (2000) Curr Opin Mol Ther 2:441-447.
    • 76—Ilan (1999) Curr Opin Mol Ther 1:116-120.
    • 77—Dubensky et al. (2000) Mol Med 6:723-732.
    • 78—Robinson & Pertmer (2000) Adv Virus Res 55:1-74.
    • 79—Donnelly et al. (2000) Am J Respir Crit Care Med 162(4 Pt 2):S190-193.
    • 80—Davis (1999) Mt. Sinai J. Med. 66:84-90.
    • 81—Parkhill et al. (2000) Nature 404:502-506.
  • SEQUENCE LISTING
    741 from strain 1000
    SEQ ID 1
    MTRSKPVNRTAFCCLSLTAALILTACSSGGGGVAADIGAGLADAL
    TTPLDHKDKSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNT
    GKLKNDKVSRFDFIRQIEVDGQTITLASGEFQIYKQNHSAVVALQ
    IEKINNPDKIDSLINQRSFLVSGLGGEHTAFNQLPDGKAEYHGKA
    FSSDDPNGRLHYSIDFTKKQGYGRIEHLKTPEQNVELASAELKAD
    EKSHAVILGDTRYGGEEKGTYHLALFGDRAQEIAGSATVKIREKV
    HEIGIAGKQ
    741 from strain 2201731
    (premature stop codon, though reliable sequence)
    SEQ ID 2
    MTRSKPVNRTAFCCLSLTTALILTACSSGGGGVAADIGAGLADAL
    TAPLDHKDKGLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNT
    GKLKNDKVSRFDFIRQIEVDGQLITLESGEFQVYKQSHSALTAFQ
    TEQIQDSEHSGKMVAKRQFRIGDIAGEHTSFDKLPEGGRATYRGT
    AFGSDDAGGKLTYTIDFAAKQGNGKIEHLKSPELNVDLAAADIKP
    DGKRHAVISGSVLYNQAEKGSYSLGIFGGKA
    741 from strain 90/18311 (incomplete) 
    SEQ ID 3
    GLADALTAPLDHKDKSLQSLTLDQSVRKNEKLKLAAQGAEKTYGN
    GDSLNTGKLKNDKVSRFDFIRQIEVDGQLITLESGEFQIYKQDHS
    AVVALQIEKINNPDKIDSLINQRSFLVSGLGGEHTAFNQLPSGKA
    EYHGKAFSSDDPNGRLHYSIDFTKKQGYGRIEHLKTPEQNVELAS
    AELKADEKSHAVILGDTRYGGEEKGTYHLALFGDRAQEIAGSATV
    KIREKVHET
    741 from strain L93/4286 (incomplete)
    SEQ ID 4
    VAADIGAGLADALTAPLDHKDKGLQSLMLDQSVRKNEKLKLAAQG
    AEKTYGNGDSLNTGKLKNDKVSRFDFIRQIEVDGQTITLASGEFQ
    IYKQNHSAVVALQIEKINNPDKIDSLINQRSFLVSGLGGEHTAFN
    QLPDGKAEYHGKAFSSDDPNGRLHYSIDFTKKQGYGRIEHLKTPE
    QNVELASAELKADEKSHAVILGDTRYGGEEKGTYHLALFGDRAQE
    IAGSATVKIREKVHEIGIAGKQ
    741 from strain 2996
    SEQ ID 5
    MTRSKPVNRTAFCCLSLTAALILTACSSGGGGVAADIGAGLADAL
    TAPLDHKDKSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNT
    GKLKNDKVSRFDFIRQIEVDGQLITLESGEFQIYKQDHSAVVALQ
    IEKINNPDKIDSLINQRSFLVSGLGGEHTAFNQLPDGKAEYHGKA
    FSSDDAGGKLTYTIDFAAKQGHGKIEHLKTPEQNVELAAAELKAD
    EKSHAVILGDTRYGSEEKGTYHLALFGDRAQEIAGSATVKIGEKV
    HEIGIAGKQ
    741 from strain 30/00
    SEQ ID 6
    KDKGLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNTGKLKND
    KVSRFDFIRQIEVDGQLITLESGEFQVYKQSHSALTAFQTEQIQD
    SEHSGKMVAKRQFRIGDIAGEHTSFDKLPEGGRATYRGTAFGSDD
    AGGKLTYTIDFAAKQGNGKIEHLKSPELNVDLAAADIKPDGKRHA
    VISGSVLYNQAEKGSYSLGIFGGKAQEVAGSAEVKTVNGIRHIGL
    AAKQ
    741 from strain 312294
    SEQ ID 7
    MTRSKPVNRTAFCCLSLTAALILTACSSGGGGVAADIGAGLADAL
    TAPLDHKDKSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNT
    GKLKNDKVSRFDFIRQIEVDGQLITLESGEFQIYKQDHSAVVALQ
    IEKINNPDKIDSLINQRSFLVSGLGGEHTAFNQLPDGKAEYHGKA
    FSSDDAGGKLTYTIDFAAKQGHGKIEHLKTPEQNVELAAAELKAD
    EKSHAVILGDTRYGSEEKGTYHLALFGDRAQEIAGSATVKIGEKV
    HEIGIAGKQ
    741 from strain 39/99 (incomplete)
    SEQ ID 8
    DKGLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNTGKLKNDK
    VSRFDFIRQIEVDGQLITLESGEFQVYKQSHSALTAFQTEQIQDS
    EHSGKMVAKRQFRIGDIAGEHTSFDKLPEGGRATYRGTAFGSDDA
    GGKLTYTIDFAAKQGNGKIEHLKSPELNVDLAAADIKPDGKRHAV
    ISGSVLYNQAEKGSYSLGIFGGKAQEVAGSAEVKTVNGIRHIGLA
    AKQ
    741 from strain 5/99
    SEQ ID 9
    MTRSKPVNRTAFCCLSLTAALILTACSSGGGGVAADIGAGLADAL
    TAPLDHKDKGLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNT
    GKLKNDKVSRFDFIRQIEVDGQLITLESGEFQIYKQDHSAVVALQ
    IEKINNPDKIDSLINQRSFLVSGLGGEHTAFNQLPSGKAEYHGKA
    FSSDDPNGRLHYSIDFTKKQGYGRIEHLKTPEQNVELASAELKAD
    EKSHAVILGDTRYGGEEKGTYHLALFGDRAQEIAGSATVKIREKV
    HEIGIAGKQ
    741 from strain 67/00
    SEQ ID 10
    MTRSKPVNRTAFCCFSLTAALILTACSSGGGGVAADIGAGLADAL
    TAPLDHKDKSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNT
    GKLKNDKVSRFDFIRQIEVDGQLITLESGEFQVYKQSHSALTALQ
    TEQEQDPEHSGKMVAKRRFKIGDIAGEHTSFDKLPKDVMATYRGT
    AFGSDDAGGKLTYTIDFAAKQGHGKIEHLKSPELNVELATAYIKP
    DEKHHAVISGSVLYNQDEKGSYSLGIFGGQAQEVAGSAEVETANG
    IHHIGLAAKQ
    741 from strain BZ169
    SEQ ID 11
    LQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNTGKLKNDKVSR
    FDFIRQIEVDGQLITLESGEFQVYKQSHSALTAFQTEQIQDSEHS
    GKMVAKRQFRIGDIAGEHTSFDKLPEGGRATYRGTAFGSDDAGGK
    LTYTIDFAAKQGNGKIEHLKSPELNVDLAAADIKPDGKRHAVISG
    SVLYNQAEKGSYSLGIFGGKAQEVAGSAEVKTVNGIRHIGLAAKQ
    741 from strain 72/00
    SEQ ID 12
    LQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNTGKLKNDKVSR
    FDFIRQIEVDGQLITLESGEFQVYKQSHSALTAFQTEQIQDSEHS
    GKMVAKRQFRIGDIAGEHTSFDKLPEGGRATYRGTAFGSDDAGGK
    LTYTIDFAAKQGNGKIEHLKSPELNVDLAAADIKPDGKRHAVISG
    SVLYNQAEKGSYSLGIFGGKAQEVAGSAEVKTVNGIRHIGLAAKQ
    741 from strain 93/114
    SEQ ID 13
    MTRSKPVNRTAFCCFSLTAALILTACSSGGGGVAADIGAGLADAL
    TAPLDHKDKSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNT
    GKLKNDKVSRFDFIRQIEVDGQLITLESGEFQVYKQSHSALTALQ
    TEQEQDPEHSGKMVAKRRFKIGDIAGEHTSFDKLPKDVMATYRGT
    AFGSDDAGGKLTYTIDFAAKQGHGKIEHLKSPELNVELATAYIKP
    DEKHHAVISGSVLYNQDEKGSYSLGIFGGQAQEVAGSAEVETANG
    IHHIGLAAKQ
    741 from strain 95N477
    SEQ ID 14
    MTRSKPVNRTAFCCLSLTAALILTACSSGGGGVAADIGAGLADAL
    TAPLDHKDKSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNT
    GKLKNDKVSRFDFIRQIEVDGQLITLESGEFQIYKQDHSAVVALQ
    IEKINNPDKIDSLINQRSFLVSGLGGEHTAFNQLPSGKAEYHGKA
    FSSDDPNGRLHYSIDFTKKQGYGRIEHLKTPEQNVELASAELKAD
    EKSHAVILGDTRYGGEEKGTYHLALFGDRAQEIAGSATVKIREKV
    HEIGIAGKQ
    741 from strain 96217
    SEQ ID 15
    MTRSKPVNRTAFCCLSLTAALILTACSSGGGGVAADIGAGLADAL
    TAPLDHKDKSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNT
    GKLKNDKVSRFDFIRQIEVDGQLITLESGEFQIYKQDHSAVVALQ
    IEKINNPDKIDSLINQRSFLVSGLGGEHTAFNQLPDGKAEYHGKA
    FSSDDAGGKLTYTIDFAAKQGHGKIEHLKTPEQNVELAAAELKAD
    EKSHAVILGDTRYGSEEKGTYHLALFGDRAQEIAGSATVKIGEKV
    HEIGIAGKQ
    741 from strain BZ133
    SEQ ID 16
    MTRSKPVNRTAFCCLSLTAALILTACSSGGGGVAADIGAGLADAL
    TAPLDHKDKSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNT
    GKLKNDKVSRFDFIRQIEVDGQLITLESGEFQVYKQSHSALTALQ
    TEQVQDSEHSGKMVAKRQFRIGDIAGEHTSFDKLPEGGRATYRGT
    AFGSDDASGKLTYTIDFAAKQGHGKIEHLKSPELNVDLAASDIKP
    DKKRHAVISGSVLYNQAEKGSYSLGIFGGQAQEVAGSAEVETANG
    IRHIGLAAKQ
    741 from strain BZ232
    SEQ ID 17
    MTRSKPVNRTAFCCLSLTAALILTACSSGGGGVAADIGAGLADAL
    TAPLDHKDKSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNT
    GKLKNDKVSRFDFIRQIEVDGQTITLASGEFQIYKQNHSAVVALQ
    IEKINNPDKIDSLINQRSFLVSGLGGEHTAFNQLPDGKAEYHGKA
    FSSDDPNGRLHYSIDFTKKQGYGRIEHLKTPEQNVELASAELKAD
    EKSHAVILGDTRYGGEEKGTYHLALFGDRAQEIAGSATVKIREKV
    HEIGIAGKQ
    741 from strain C11
    SEQ ID 18
    MTRSKPVNRTAFCCLSLTAALILTACSSGGGGVAADIGAGLADAL
    TAPLDHKDKSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNT
    GKLKNDKVSRFDFIRQIEVDGQLITLESGEFQIYKQDHSAVVALQ
    IEKINNPDKIDSLINQRSFLVSGLGGEHTAFNQLPSGKAEYHGKA
    FSSDDPNGRLHYSIDFTKKQGYGRIEHLKTPEQNVELASAELKAD
    EKSHAVILGDTRYGGEEKGTYHLALFGDRAQEIAGSATVKIREKV
    HEIGIAGKQ
    741 from strain M1090
    SEQ ID 19
    MTRSKPVNRTAFCCLSLTAALILTACSSGGGGVAADIGAGLADAL
    TAPLDHKDKSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNT
    GKLKNDKVSRFDFIRQIEVDGQLITLESGEFQIYKQDHSAVVALQ
    IEKINNPDKIDSLINQRSFLVSGLGGEHTAFNQLPSGKAEYHGKA
    FSSDDAGGKLTYTIDFAAKQGHGKIEHLKTPEQNVELASAELKAD
    EKSHAVILGDTRYGGEEKGTYHLALFGDRAQEIAGSATVKIREKV
    HEIGIAGKQ
    741 from strain M1096
    SEQ ID 20
    MTRSKPVNRTAFCCLSLTAALILTACSSGGGGVAADIGAGLADAL
    TTPLDHKDKSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNT
    GKLKNDKVSRFDFIRQIEVDGQTITLASGEFQIYKQNHSAVVALQ
    IEKINNPDKIDSLINQRSFLVSGLGGEHTAFNQLPDGKAEYHGKA
    FSSDDPNGRLHYSIDFTKKQGYGRIEHLKTPEQNVELASAELKAD
    EKSHAVILGDTRYGGEEKGTYHLALFGDRAQEIAGSATVKIREKV
    HEIGIAGKQ
    741 from strain M198/172
    SEQ ID 21
    MTRSKPVNRTAFCCLSLTAALILTACSSGGGGVAADIGAGLADAL
    TAPLDHKDKSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNT
    GKLKNDKVSRFDFIRQIEVDGQLITLESGEFQVYKQSHSALTALQ
    TEQVQDSEHSGKMVAKRQFRIGDIAGEHTSFDKLPEGGRATYRGT
    AFGSDDASGKLTYTIDFAAKQGHGKIEHLKSPELNVDLAASDIKP
    DKKRHAVISGSVLYNQAEKGSYSLGIFGGQAQEVAGSAEVETANG
    IRHIGLAAKQ
    741 from strain NGH38
    SEQ ID 22
    MTRSKPVNRTAFCCLSLTAALILTACSSGGGGVAADIGAGLADAL
    TAPLDHKDKSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNT
    GKLKNDKVSRFDFIRQIEVDGQTITLASGEFQIYKQNHSAVVALQ
    IEKINNPDKIDSLINQRSFLVSGLGGEHTAFNQLPDGKAEYHGKA
    FSSDDPNGRLHYSIDFTKKQGYGRIEHLKTPEQNVELASAELKAD
    EKSHAVILGDTRYGGEEKGTYHLALFGDRAQEIAGSATVKIREKV
    HEIGIAGKQ
    NMB1343 from ten meningococcal strains
    SEQ ID 23
    MGNFLYRGISCQQDEQNNGQLKPKGNKAEVAIRYDGKFKYDGKAT
    HGPSVKNAVYAHQIETGLYDGCYISTTTDKEIAKKFATSSGIENG
    YIYVLNRDLFGQYSIFEYEVEHPENPNEKEVTIRAEDCGCIPEEV
    IIAKELIEIN
    NMB1343 from gonococcus
    SEQ ID 24
    INNLWEISYLYRGISCQQDEQNNGQLKPKGNKAEVAIRYDGKFKY
    DGKATHGPSVKNAVYAHQIETDLYDGCYISTTTDKEIAKKFATSS
    GIENGYIYVLNRDLFGQYSIFEYEVEHPENPDEKEVTIRAEDCGC
    IPEEVIIAKELIEIN
    NMB1343 nucleic acid sequence (gonococcus)
    SEQ ID 25
    TCCGCCGCATTACCTTATAAAATAAAACATCCCTCTCAAGCAGTC
    TGATAATGTTTGGATTGCTTGAGATTGATGAGTGATGGTGTTAAA
    TTCAAACTTTAAATTAATAACTTATGGGAAATTTCTTATTTATAT
    AGAGGCATTAGTTGCCAACAAGATGAGCAAAATAATGGACAGTTA
    AAACCTAAAGGTAATAAAGCTGAAGTTGCAATTCGTTATGATGGT
    AAGTTTAAATATGATGGTAAAGCTACACATGGTCCAAGTGTGAAG
    AATGCAGTTTACGCCCATCAAATTGAAACAGATCTATATGACGGA
    TGTTATATATCTACGACAACAGACAAGGAAATTGCCAAGAAATTT
    GCAACAAGCTCCGGCATCGAAAATGGCTATATATATGTTTTAAAT
    AGAGATTTGTTTGGTCAATATTCTATTTTTGAATATGAGGTTGAA
    CATCCAGAAAACCCAGATGAGAAGGAAGTAACAATCAGAGCTGAA
    GATTGTGGCTGTATTCCTGAAGAAGTGATTATTGCTAAAGAGTTG
    ATAGAAATTAACTAAGTTGAAAGGTCAATATAATGGCTTTAGTTG
    AATTGAAAGTGCCCGACATTGGCGGACACGAAAATGTAGATATTA
    TCGC
    NMB1343 nucleic acid sequence (meningococcus)
    SEQ ID 26
    TCCGCCGCATTACCTTATAAAATAAAACATCCCTCTCAAGCAGTC
    TGATAATGTTTGGATTGCTTGAGATTGATGAGTAATGGTGTTAAA
    TTCAACCTTTAAATTAATAACTTATGGGAAATTTCTTATATAGAG
    GCATTAGTTGCCAACAAGATGAGCAAAATAATGGACAGTTAAAAC
    CTAAAGGTAATAAAGCTGAAGTTGCAATTCGTTATGATGGTAAGT
    TTAAATATGATGGTAAAGCTACACATGGTCCAAGTGTGAAGAATG
    CAGTTTACGCCCATCAAATTGAAACAGGTCTATATGACGGATGTT
    ATATATCTACGACAACAGACAAGGAAATTGCCAAGAAATTTGCAA
    CAAGTTCCGGCATCGAAAATGGCTATATATATGTTTTAAATAGGG
    ATTTGTTTGGTCAATATTCTATTTTTGAATATGAGGTTGAACATC
    CAGAAAACCCAAATGAGAAGGAAGTAACAATCAGAGCTGAAGATT
    GTGGCTGTATTCCTGAAGAAGTGATTATTGCTAAAGAGTTGATAG
    AAATTAACTAAGTTGAAAGGTCAATATAATGGCTTTAGTTGAATT
    GAAAGTGCCCGACATTGGCGGACACGAAAATGTAGATATTATCGC
    linker
    SEQ ID 27
    GSGGGG
    preferred ΔG287NZ-953 hybrid
    SEQ ID 28
    MASPDVKSADTLSKPAAPVVAEKETEVKEDAPQAGSQGQGAPSTQ
    GSQDMAAVSAENTGNGGAATTDKPKNEDEGPQNDMPQNSAESANQ
    TGNNQPADSSDSAPASNPAPANGGSNFGRVDLANGVLIDGPSQNI
    TLTHCKGDSCNGDNLLDEEAPSKSEFENLNESERIEKYKKDGKSD
    KFTNLVATAVQANGTNKYVIIYKDKSASSSSARFRRSARSRRSLP
    AEMPLIPVNQADTLIVDGEAVSLTGHSGNIFAPEGNYRYLTYGAE
    KLPGGSYALRVQGEPAKGEMLAGTAVYNGEVLHFHTENGRPYPTR
    GRFAAKVDFGSKSVDGIIDSGDDLHMGTQKFKAAIDGNGFKGTWT
    ENGGGDVSGRFYGPAGEEVAGKYSYRPTDAEKGGFGVFAGKKEQD
    GSGGGGATYKVDEYHANARFAIDHFNTSTNVGGFYGLTGSVEFDQ
    AKRDGKIDITIPVANLQSGSQHFTDHLKSADIFDAAQYPDIRFVS
    TKFNFNGKKLVSVDGNLTMHGKTAPVKLKAEKFNCYQSPMAKTEV
    CGGDFSTTIDRTKWGVDYLVNVGMTKSVRIDIQIEAAKQ
    ΔG287NZ-953 hybrid
    SEQ ID 29
    MASPDVKSADTLSKPAAPVVSEKETEAKEDAPQAGSQGQGAPSAQ
    GGQDMAAVSEENTGNGGAAATDKPKNEDEGAQNDMPQNAADTDSL
    TPNHTPASNMPAGNMENQAPDAGESEQPANQPDMANTADGMQGDD
    PSAGGENAGNTAAQGTNQAENNQTAGSQNPASSTNPSATNSGGDF
    GRTNVGNSVVIDGPSQNITLTHCKGDSCSGNNFLDEEVQLKSEFE
    KLSDADKISNYKKDGKNDGKNDKFVGLVADSVQMKGINQYIIFYK
    PKPTSFARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTG
    HSGNIFAPEGNYRYLTYGAEKLPGGSYALRVQGEPSKGEMLAGTA
    VYNGEVLHFHTENGRPSPSRGRFAAKVDFGSKSVDGIIDSGDGLH
    MGTQKFKAAIDGNGFKGTWTENGGGDVSGKFYGPAGEEVAGKYSY
    RPTDAEKGGFGVFAGKKEQDGSGGGGATYKVDEYHANARFAIDHF
    NTSTNVGGFYGLTGSVEFDQAKRDGKIDITIPVANLQSGSQHFTD
    HLKSADIFDAAQYPDIRFVSTKFNFNGKKLVSVDGNLTMHGKTAP
    VKLKAEKFNCYQSPMAKTEVCGGDFSTTIDRTKWGVDYLVNVGMT
    KSVRIDIQIEAAKQ
    936-ΔG741 hybrid
    SEQ ID 30
    MKPKPHTVRTLIAAIFSLALSGCVSAVIGSAAVGAKSAVDRRTTG
    AQTDDNVMALRIETTARSYLRQNNQTKGYTPQISVVGYNRHLLLL
    GQVATEGEKQFVGQIARSEQAAEGVYNYITVASLPRTAGDIAGDT
    WNTSKVRATLLGISPATQARVKIVTYGNVTYVMGILTPEEQAQIT
    QKVSTTVGVQKVITLYQNYVQRGSGGGGVAADIGAGLADALTAPL
    DHKDKGLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDSLNTGKLK
    NDKVSRFDFIRQIEVDGQLITLESGEFQVYKQSHSALTAFQTEQI
    QDSEHSGKMVAKRQFRIGDIAGEHTSFDKLPEGGRATYRGTAFGS
    DDAGGKLTYTIDFAAKQGNGKIEHLKSPELNVDLAAADIKPDGKR
    HAVISGSVLYNQAEKGSYSLGIFGGKAQEVAGSAEVKTVNGIRHI
    GLAAKQ
    961c
    SEQ ID 31
    MATNDDDVKKAATVAIAAAYNNGQEINGFKAGETIYDIDEDGTIT
    KKDATAADVEADDFKGLGLKKVVTNLTKTVNENKQNVDAKVKAAE
    SEIEKLTTKLADTDAALADTDAALDATTNALNKLGENITTFAEET
    KTNIVKIDEKLEAVADTVDKHAEAFNDIADSLDETNTKADEAVKT
    ANEAKQTAEETKQNVDAKVKAAETAAGKAEAAAGTANTAADKAEA
    VAAKVTDIKADIATNKDNIAKKANSADVYTREESDSKFVRIDGLN
    ATTEKLDTRLASAEKSIADHDTRLNGLDKTVSDLRKETRQGLAEQ
    AALSGLFQPYNVG

Claims (21)

1. (canceled)
2. A purified polypeptide comprising (i) an amino acid sequence having at least 80% identity to SEQ ID NO: 3, or (ii) at least 50 consecutive amino acids from SEQ ID NO: 3.
3. The purified polypeptide of claim 2, wherein the amino acid sequence has at least 90% identity to SEQ ID NO: 3.
4. The purified polypeptide of claim 2, wherein the polypeptide comprises at least 60 consecutive amino acids from SEQ ID NO: 3.
5. A method of inducing an immune response in a subject comprising administering to the subject an effective amount of a composition comprising the purified polypeptide of claim 2.
6. The method of claim 5, wherein the composition comprises an aluminum salt adjuvant.
7. The method of claim 6, wherein the purified polypeptide is adsorbed to the aluminum salt adjuvant.
8. The method of claim 6, wherein the aluminum salt adjuvant comprises aluminum phosphate.
9. The method of claim 7, wherein the aluminum salt adjuvant comprises aluminum phosphate.
10. The method of claim 6, wherein the aluminum salt adjuvant comprises aluminum phosphate.
11. The method of claim 7, wherein the aluminum salt adjuvant comprises aluminum phosphate.
12. A purified protein having formula:

NH2-A-[—X-L-]n-B—COOH
wherein L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is 2 and X is an amino acid sequence comprising at least 40 consecutive amino acids from a 741 protein, wherein the first 741 protein is SEQ ID NO: 3 and the second 741 protein is SEQ ID NO: 7.
13. A composition comprising the purified protein of claim 12 adsorbed to an aluminum salt adjuvant.
14. A composition comprising the purified protein of claim 12 and an aluminum hydroxyphosphate adjuvant.
15. A method of inducing an immune response in a subject comprising administering to the subject an effective amount of a composition comprising the purified polypeptide of claim 12.
16. The method of claim 15, wherein the composition comprises an aluminum salt adjuvant.
17. The method of claim 16, wherein the purified polypeptide is adsorbed to the aluminum salt adjuvant.
18. The method of claim 16, wherein the aluminum salt adjuvant comprises aluminum phosphate.
19. The method of claim 17, wherein the aluminum salt adjuvant comprises aluminum phosphate.
20. The method of claim 16, wherein the aluminum salt adjuvant comprises aluminum phosphate.
21. The method of claim 17, wherein the aluminum salt adjuvant comprises aluminum phosphate.
US14/739,985 2001-09-06 2015-06-15 Methods of inducing an immune response with compositions comprising a neisseria meningitidis 741 protein Abandoned US20150273044A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/739,985 US20150273044A1 (en) 2001-09-06 2015-06-15 Methods of inducing an immune response with compositions comprising a neisseria meningitidis 741 protein
US15/802,347 US20180169210A1 (en) 2001-09-06 2017-11-02 Hybrid and tandem expression of neisserial proteins

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB0121591.2A GB0121591D0 (en) 2001-09-06 2001-09-06 Hybrid and tandem expression of neisserial proteins
GB0121591.2 2001-09-06
PCT/IB2002/003904 WO2003020756A2 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial proteins
US48878605A 2005-02-25 2005-02-25
US13/366,252 US8840907B2 (en) 2001-09-06 2012-02-03 Isolated protein and compositions comprising the protein
US14/305,979 US9056075B2 (en) 2001-09-06 2014-06-16 Methods of inducing an immune response with compositions comprising a Neisseria meningitidis 741 protein
US14/739,985 US20150273044A1 (en) 2001-09-06 2015-06-15 Methods of inducing an immune response with compositions comprising a neisseria meningitidis 741 protein

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/305,979 Continuation US9056075B2 (en) 2001-09-06 2014-06-16 Methods of inducing an immune response with compositions comprising a Neisseria meningitidis 741 protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/802,347 Continuation US20180169210A1 (en) 2001-09-06 2017-11-02 Hybrid and tandem expression of neisserial proteins

Publications (1)

Publication Number Publication Date
US20150273044A1 true US20150273044A1 (en) 2015-10-01

Family

ID=9921633

Family Applications (6)

Application Number Title Priority Date Filing Date
US10/488,786 Active 2027-01-24 US8980277B2 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial proteins
US13/159,370 Expired - Fee Related US9011869B2 (en) 2001-09-06 2011-06-13 Hybrid and tandem expression of Neisserial proteins
US13/366,252 Expired - Fee Related US8840907B2 (en) 2001-09-06 2012-02-03 Isolated protein and compositions comprising the protein
US14/305,979 Expired - Fee Related US9056075B2 (en) 2001-09-06 2014-06-16 Methods of inducing an immune response with compositions comprising a Neisseria meningitidis 741 protein
US14/739,985 Abandoned US20150273044A1 (en) 2001-09-06 2015-06-15 Methods of inducing an immune response with compositions comprising a neisseria meningitidis 741 protein
US15/802,347 Abandoned US20180169210A1 (en) 2001-09-06 2017-11-02 Hybrid and tandem expression of neisserial proteins

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US10/488,786 Active 2027-01-24 US8980277B2 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial proteins
US13/159,370 Expired - Fee Related US9011869B2 (en) 2001-09-06 2011-06-13 Hybrid and tandem expression of Neisserial proteins
US13/366,252 Expired - Fee Related US8840907B2 (en) 2001-09-06 2012-02-03 Isolated protein and compositions comprising the protein
US14/305,979 Expired - Fee Related US9056075B2 (en) 2001-09-06 2014-06-16 Methods of inducing an immune response with compositions comprising a Neisseria meningitidis 741 protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/802,347 Abandoned US20180169210A1 (en) 2001-09-06 2017-11-02 Hybrid and tandem expression of neisserial proteins

Country Status (18)

Country Link
US (6) US8980277B2 (en)
EP (4) EP2327719B1 (en)
JP (4) JP4511832B2 (en)
CN (2) CN100390196C (en)
AT (1) ATE496063T1 (en)
AU (2) AU2002339217B2 (en)
BR (1) BR0212363A (en)
CA (1) CA2459816C (en)
CY (2) CY1113218T1 (en)
DE (1) DE60238993D1 (en)
DK (3) DK2360176T3 (en)
ES (3) ES2523365T3 (en)
GB (1) GB0121591D0 (en)
MX (2) MXPA04002216A (en)
NZ (3) NZ532115A (en)
PT (3) PT2327719E (en)
RU (2) RU2339646C2 (en)
WO (1) WO2003020756A2 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1047784E (en) * 1998-01-14 2009-12-21 Novartis Vaccines & Diagnostic Neissera meningitidis antigens
EP2261343A3 (en) 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
PT1228217E (en) 1999-04-30 2013-01-28 Novartis Vaccines & Diagnostic Conserved neisserial antigens
CA2929348A1 (en) * 1999-05-19 2000-11-30 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
ES2564463T3 (en) * 1999-10-29 2016-03-22 Glaxosmithkline Biologicals S.A. Neisserial antigenic peptides
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
BRPI0107679B8 (en) 2000-01-17 2021-05-25 Chiron Spa composition comprising Neisseria meningitidis serum group b outer membrane vesicles and an inorganic component and use thereof
CN100339482C (en) 2000-02-28 2007-09-26 启龙股份公司 Hybrid expression of neisserial proteins
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
BR0211494A (en) 2001-07-27 2004-08-17 Chiron Srl Meningococcal adhesins nothing, app and orf 40
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
US7838015B2 (en) 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
NZ574530A (en) 2002-08-02 2010-12-24 Glaxosmithkline Biolog Sa Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB-neisseria minigitidis
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP2351579B1 (en) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
EP2279746B1 (en) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ATE552844T1 (en) 2003-01-30 2012-04-15 Novartis Ag INJECTABLE VACCINE AGAINST MULTIPLE MENINGOCOCC SEROGROUPES
BR122017002991B1 (en) 2003-10-02 2023-01-10 Novartis Vaccines And Diagnostics S.R.L. AQUEOUS IMMUNOGENIC COMPOSITIONS FOR MULTIPLE MENINGOCOCCAL SEROGROUPS
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0415160D0 (en) * 2004-07-06 2004-08-11 Chiron Srl Inhibitors of bacterial infection
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
ATE552267T1 (en) 2005-02-18 2012-04-15 Novartis Vaccines & Diagnostic IMMUGENES OF UROPATHOGENS ESCHERICHIA COLI
DK1858920T3 (en) 2005-02-18 2016-02-29 Glaxosmithkline Biolog Sa PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS / SEPSIS-ASSOCIATED ESCHERICHIA COLI
AU2013201318B2 (en) * 2005-11-25 2015-11-19 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US20110008279A1 (en) * 2005-12-06 2011-01-13 Vega Masignani Methods and Compositions Relating to Adhesins as Adjuvants
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
CN101951949B (en) 2007-10-19 2013-10-02 诺华股份有限公司 Meningococcal vaccine formulations
EP2886551A3 (en) 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
CA2716706C (en) 2008-03-03 2014-02-18 Irm Llc Compounds and compositions as tlr activity modulators
ES2557282T3 (en) * 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Chimeric H-factor binding proteins (fHBP) containing a heterologous B domain, and methods of use
WO2009150531A1 (en) * 2008-06-09 2009-12-17 Novartis Ag Antibodies against neisserial factor h binding protein
NZ593674A (en) * 2008-12-17 2013-03-28 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
BRPI1013902A2 (en) * 2009-04-30 2019-09-24 Children´S Hospital & Res Center At Oakland chimeric factor binding protein h (fhbp) is method of use
CN102762226A (en) 2009-06-10 2012-10-31 诺华有限公司 Benzonaphthyridine-containing vaccines
EP2443250B8 (en) 2009-06-16 2016-09-21 GlaxoSmithKline Biologicals SA High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
CA2772104A1 (en) * 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
TWI445708B (en) 2009-09-02 2014-07-21 Irm Llc Compounds and compositions as tlr activity modulators
JP5988492B2 (en) 2009-09-02 2016-09-07 ノバルティス アーゲー Immunogenic composition comprising a TLR activity modulator
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
MX2012004850A (en) 2009-10-27 2012-05-22 Novartis Ag Modified meningococcal fhbp polypeptides.
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
EP2512478B1 (en) 2009-12-15 2017-04-19 GlaxoSmithKline Biologicals SA Homogeneous suspension of immunopotentiating compounds and uses thereof
JP5363381B2 (en) * 2010-03-09 2013-12-11 パナソニック株式会社 Plasma display panel
WO2011119759A1 (en) 2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
BR122021020829B8 (en) 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland NON-NATURALLY OCCURRING FACTOR H-BINDING PROTEIN (FHBP), COMPOSITION, AND GENETICALLY MODIFIED NEISSERIA MENINGITIDIS HOST CELL
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
CN103189071A (en) 2010-08-23 2013-07-03 惠氏有限责任公司 Stable formulations of neisseria meningitidis rLP2086 antigens
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
EP2613805B1 (en) 2010-09-10 2019-10-23 GlaxoSmithKline Biologicals SA Meningococcus overexpressing nada and/or nhba and outer membrane vesicles derived therefrom
CN102028941B (en) * 2011-02-11 2013-02-13 中国医学科学院医学生物学研究所 Neisseria meningitidis group B recombinant protein chimeric vaccine and preparation method thereof
US20140186861A1 (en) * 2011-07-11 2014-07-03 Uvic Industry Partnerships Inc. Soluble treponema pallidum protein tp0453, tp0453-tp0326 fusion protein, and use in syphilis diagnosis
WO2013098589A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
AU2013229063B2 (en) 2012-03-09 2016-10-06 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
RU2644340C2 (en) 2012-06-14 2018-02-08 Новартис Аг Vaccines for serogroup x meningococcus
WO2014016152A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
AU2014296027A1 (en) * 2013-08-02 2016-02-04 Children's Hospital & Research Center At Oakland Non-naturally occurring factor H binding proteins (fHbp) and methods of use thereof
KR102199096B1 (en) 2013-09-08 2021-01-06 화이자 인코포레이티드 Neisseria meningitidis compositions and methods thereof
AU2015222121B2 (en) 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
NZ766005A (en) 2014-07-23 2024-03-22 Children’S Hospital & Res Center At Oakland Factor h binding protein variants and methods of use thereof
RU2723045C2 (en) 2015-02-19 2020-06-08 Пфайзер Инк. Compositions of neisseria meningitidis and methods for preparation thereof
CA3035320A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3211240A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024030931A1 (en) 2022-08-03 2024-02-08 Sanofi Pasteur Inc. Adjuvanted immunogenic composition against neisseria meningitidis b

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196056B1 (en) 1985-03-28 1991-05-22 Chiron Corporation Improved expression using fused genes providing for protein product
DE3622221A1 (en) * 1986-07-02 1988-01-14 Max Planck Gesellschaft METHOD FOR THE GENE-TECHNOLOGICAL EXTRACTION OF PROTEINS USING GRAM-NEGATIVE HOST CELLS
EP0273116A3 (en) 1986-10-09 1990-05-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gonococcal and meningococcal polypeptides, vaccines and diagnostics
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
ES2070312T5 (en) 1988-12-19 2003-05-16 American Cyanamid Co CLASS 1 MENINGOCOCIC EXTERNAL MEMBRANE PROTEIN VACCINE.
NL8803111A (en) 1988-12-19 1990-07-16 Nederlanden Staat Meningococcus class 1 outer-membrane protein vaccine - useful to immunise against meningococcal disease
DE68907045T2 (en) 1989-01-17 1993-12-02 Eniricerche Spa Synthetic peptides and their use as general carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
ES2071288T3 (en) * 1989-12-14 1995-06-16 Ca Nat Research Council IMPROVED VACCINE OF MENINGOCOCCAL POLYSACCHARIDE CONJUGATE.
CU22302A1 (en) * 1990-09-07 1995-01-31 Cigb Codifying nucleotidic sequence for a protein of the external membrane of neisseria meningitidis and the use of that protein in preparing vaccines.
IE912559A1 (en) 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ES2127217T3 (en) 1991-03-14 1999-04-16 Imclone Systems Inc RECOMBINATION HYBRID PORINE EPITOPES.
EP0967279B1 (en) 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
FR2692592B1 (en) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc DNA fragments encoding the Neisseria meningitidis transferrin receptor subunits and methods of expressing them.
ATE188613T1 (en) 1992-06-25 2000-01-15 Smithkline Beecham Biolog VACCINE COMPOSITION CONTAINING ADJUVANTS
JP4028593B2 (en) 1993-03-23 2007-12-26 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム 3-O deacylated monophosphoryl lipid A-containing vaccine composition
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6165747A (en) 1993-12-30 2000-12-26 President & Fellows Of Harvard College Nucleic acids encoding hedgehog proteins
FR2720408B1 (en) 1994-05-31 1996-08-14 Pasteur Merieux Serums Vacc Fragments Tbp2 of Neisseria meningitidis.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
IL117483A (en) * 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
FR2739624B1 (en) 1995-10-10 1997-12-05 Pasteur Merieux Serums Vacc NEW NEISSERIA MENINGITIDIS TBP2 SUBUNIT
DE19630390A1 (en) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteins, in particular membrane proteins from Helicobacter pylori, their production and use
ES2241042T3 (en) 1996-10-11 2005-10-16 The Regents Of The University Of California IMMUNO STIMULATOR POLINUCLEOTIDE CONJUGATES / IMMUNOMODULATOR MOLECULA.
US6472518B1 (en) 1996-10-24 2002-10-29 Centers For Disease Control And Prevention, As Represented By The Secretary, Department Of Health And Human Services Invasion associated genes from Neisseria meningitidis serogroup B
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
EP1003850B1 (en) 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
CA2308606A1 (en) * 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
ATE352624T1 (en) 1997-11-21 2007-02-15 Serono Genetics Inst Sa CHLAMYDIA PNEUMONIAE GENOMIC SEQUENCES AND POLYPEPTIDES, FRAGMENTS AND APPLICATIONS THEREOF FOR DETECTION, PREVENTION AND CURE
EP2218731A1 (en) 1997-11-28 2010-08-18 Merck Serono Biodevelopment Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
PT1047784E (en) 1998-01-14 2009-12-21 Novartis Vaccines & Diagnostic Neissera meningitidis antigens
KR100627590B1 (en) 1998-01-30 2006-09-25 다이이치 아스비오파마 가부시키가이샤 Process for producing peptide with the use of accessory peptide
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
EP2261343A3 (en) 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
EP1559795A3 (en) 1998-10-09 2005-11-09 Chiron Corporation Neisseria genomic sequences and methods of their use
HU228473B1 (en) 1998-10-16 2013-03-28 Smithkline Beecham Biolog Adjuvant systems and vaccines
DK1535928T3 (en) * 1998-10-22 2008-10-20 Univ Montana Vaccine Compositions Containing Omp85 Proteins of Neisseria gonorrhoeae and Neisseria meningitidis
CA2350775A1 (en) 1998-11-12 2000-05-18 The Regents Of The University Of California Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
JP2002540074A (en) 1999-03-19 2002-11-26 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム vaccine
FR2791895B1 (en) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc USE OF TREHALOSE TO STABILIZE A LIQUID VACCINE
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
BRPI0010612B8 (en) 1999-04-19 2021-05-25 Smithkline Beecham Biologicals S A vaccines
CN1359426A (en) 1999-04-30 2002-07-17 希龙公司 Neisseria genomic sequences and methods of their use
PT1228217E (en) 1999-04-30 2013-01-28 Novartis Vaccines & Diagnostic Conserved neisserial antigens
CA2929348A1 (en) 1999-05-19 2000-11-30 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
HUP0202885A3 (en) 1999-09-24 2004-07-28 Smithkline Beecham Biolog Vaccines
TR200200777T2 (en) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. At least one non-ionic surfactant adjuvant with polyoxyethylene alkyl ether or ester.
ES2564463T3 (en) 1999-10-29 2016-03-22 Glaxosmithkline Biologicals S.A. Neisserial antigenic peptides
BRPI0107679B8 (en) 2000-01-17 2021-05-25 Chiron Spa composition comprising Neisseria meningitidis serum group b outer membrane vesicles and an inorganic component and use thereof
ES2389719T3 (en) 2000-01-25 2012-10-30 The University Of Queensland Proteins comprising conserved regions of the Neisseria meningitidis NhhA surface antigen
CN100339482C (en) 2000-02-28 2007-09-26 启龙股份公司 Hybrid expression of neisserial proteins
US20040167058A1 (en) * 2000-06-29 2004-08-26 Colgate-Palmolive Company Multi-phase clear fabric softening composition
ATE440861T1 (en) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic IMMUNIZATION AGAINST CHLAMYDIA PNEUMONIAE
IL154853A0 (en) 2000-10-27 2003-10-31 Chiron Spa Nucleic acids and proteins from streptococcus groups a & b
GB0108024D0 (en) 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AU2002330681C1 (en) 2001-07-26 2015-04-02 Glaxosmithkline Biologicals S.A. Vaccines comprising aluminium adjuvants and histidine
BR0211494A (en) 2001-07-27 2004-08-17 Chiron Srl Meningococcal adhesins nothing, app and orf 40
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
NZ574530A (en) 2002-08-02 2010-12-24 Glaxosmithkline Biolog Sa Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB-neisseria minigitidis
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP2351579B1 (en) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2512917A1 (en) 2003-01-15 2004-08-05 Wyeth Holdings Corporation Methods for increasing neisseria protein expression
ATE552844T1 (en) 2003-01-30 2012-04-15 Novartis Ag INJECTABLE VACCINE AGAINST MULTIPLE MENINGOCOCC SEROGROUPES
US20070253964A1 (en) 2003-04-16 2007-11-01 Zlotnick Gary W Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
BR122017002991B1 (en) 2003-10-02 2023-01-10 Novartis Vaccines And Diagnostics S.R.L. AQUEOUS IMMUNOGENIC COMPOSITIONS FOR MULTIPLE MENINGOCOCCAL SEROGROUPS
GB0409748D0 (en) 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
AR051836A1 (en) 2004-11-30 2007-02-14 Centocor Inc RECEIVER ANTAGONISTS 3 SIMIL TOLL METHODS AND USES
CN101107007B (en) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
US20100150912A1 (en) 2007-04-11 2010-06-17 Novartis Ag Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
IN2009KN04098A (en) 2007-06-04 2015-08-28 Novartis Ag
EP2886551A3 (en) 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
ES2557282T3 (en) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Chimeric H-factor binding proteins (fHBP) containing a heterologous B domain, and methods of use
IT1394288B1 (en) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic PROTEIN IMMUNOGENES THAT LINK THE FACTOR H.
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
EP2613805B1 (en) 2010-09-10 2019-10-23 GlaxoSmithKline Biologicals SA Meningococcus overexpressing nada and/or nhba and outer membrane vesicles derived therefrom

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Parkhill et al (Accession Number G81977, May 5, 2000). *
Tettelin et al (Accession Number D81032, March 31, 2000). *

Also Published As

Publication number Publication date
GB0121591D0 (en) 2001-10-24
JP2005350486A (en) 2005-12-22
PT2360176E (en) 2016-01-11
EP2360176A3 (en) 2012-01-18
US8980277B2 (en) 2015-03-17
JP4511832B2 (en) 2010-07-28
EP1423419A2 (en) 2004-06-02
EP2327719A1 (en) 2011-06-01
CN101260148A (en) 2008-09-10
WO2003020756A3 (en) 2003-11-20
US9011869B2 (en) 2015-04-21
NZ537976A (en) 2008-03-28
CN101260148B (en) 2012-05-09
PT2327719E (en) 2014-12-02
DE60238993D1 (en) 2011-03-03
JP5542276B2 (en) 2014-07-09
EP2327719B1 (en) 2014-08-20
US9056075B2 (en) 2015-06-16
NZ547145A (en) 2008-06-30
EP2360176B1 (en) 2015-10-21
EP1423419B1 (en) 2011-01-19
US20180169210A1 (en) 2018-06-21
DK2327719T3 (en) 2014-11-03
EP2360176A2 (en) 2011-08-24
EP2829549A2 (en) 2015-01-28
RU2339646C2 (en) 2008-11-27
US20110250223A1 (en) 2011-10-13
US20050222385A1 (en) 2005-10-06
CA2459816C (en) 2014-06-10
CN1582297A (en) 2005-02-16
ATE496063T1 (en) 2011-02-15
PT1423419E (en) 2011-03-10
EP2829549A3 (en) 2015-06-03
CY1117065T1 (en) 2017-04-05
MXPA04002216A (en) 2005-02-17
US20120195919A1 (en) 2012-08-02
JP2005508156A (en) 2005-03-31
US8840907B2 (en) 2014-09-23
NZ532115A (en) 2005-04-29
US20140294886A1 (en) 2014-10-02
WO2003020756A2 (en) 2003-03-13
RU2008122435A (en) 2009-12-10
ES2357503T3 (en) 2011-04-27
DK1423419T3 (en) 2011-04-04
JP2010252807A (en) 2010-11-11
AU2008234959A1 (en) 2008-11-13
CY1113218T1 (en) 2016-04-13
RU2004110230A (en) 2005-04-20
JP2014051497A (en) 2014-03-20
MX336118B (en) 2016-01-08
RU2475495C2 (en) 2013-02-20
ES2556770T3 (en) 2016-01-20
DK2360176T3 (en) 2015-12-14
ES2523365T3 (en) 2014-11-25
AU2002339217B2 (en) 2008-09-04
BR0212363A (en) 2004-08-10
CA2459816A1 (en) 2003-03-13
CN100390196C (en) 2008-05-28
AU2008234959B2 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
US20180169210A1 (en) Hybrid and tandem expression of neisserial proteins
AU2002339217A1 (en) Hybrid and tandem expression of Neisserial proteins
US20100233205A1 (en) Adjuvanted antigenic meningococcal compositions
AU2014201962B2 (en) Hybrid and tandem expression of Neisserial proteins
AU2012202488B2 (en) Hybrid and tandem expression of Neisserial proteins

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L., ITALY

Free format text: CHANGE OF NAME;ASSIGNOR:CHIRON S.R.L.;REEL/FRAME:035930/0128

Effective date: 20080304

Owner name: CHIRON S.R.L., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PIZZA, MARIAGRAZIA;REEL/FRAME:035934/0433

Effective date: 20041203

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS VACCINES AND DIAGNOSTICS SRL;REEL/FRAME:035977/0640

Effective date: 20140807

AS Assignment

Owner name: GLAXOSMITHKLINE BIOLOGICALS SA, BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS VACCINES AND DIAGNOSTICS SRL;REEL/FRAME:040077/0722

Effective date: 20161020

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION